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Preface 
“Improving public health control of sexually transmitted diseases in Botswana” is one of the 
institutional collaboration projects financed by the Health Sector Agreement between Norway and 
Botswana. The project has two main components; an epidemiological study and an economic 
evaluation. In 2000 and 2001, the National Health Laboratory in Gaborone, the AIDS/STD Unit and 
the Health Research Unit in the Ministry of Health in Botswana and the University of Oslo, Norway, 
conducted a cross-sectional study on sexually transmitted infections (STIs) among pregnant women 
in Gaborone. One of the aims of the study was to collect data for the cost-effectiveness analysis 
presented in this report.  
  The authors thank the Health Research Unit, Ministry of Health, for the valuable contribution 
to the formal and organizational aspects of the study. We also want to thank the staff at the 
Government Clinics and at The National Health Laboratory for their cooperation during the field 
work. The costs of the field work were covered by The Health Sector Agreement. The Norwegian 
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Abstract 
Objectives: Chlamydia is the most common bacterial sexually transmitted infection worldwide and a 
major cause of morbidity – particularly among women and neonates. We compared costs and health 
consequences of using point-of-care (POC) tests with current syndromic management among 
antenatal care attendees in sub-Saharan Africa. We also compared erythromycin with azithromycin 
treatment and universal with age-based chlamydia management. 
Methods: A decision analytic model was developed to compare diagnostic and treatment strategies, 
using Botswana as a case. Model input was based upon 1) a study of pregnant women in Botswana, 
2) literature reviews and 3) expert opinion. We expressed the study outcome in terms of costs (US$), 
cases cured, magnitude of overtreatment and successful partner treatment. 
Results: Azithromycin was less costly and more effective than was erythromycin. Compared to 
syndromic management, testing all attendees on their first visit with a 75% sensitive POC test 
increased the number of cases cured from 1 500 to 3 500 in a population of 100 000 women, at a cost 
of US$38 per additional case cured. This cost was lower in high-prevalence populations or if testing 
was restricted to teenagers. The specific POC tests provided the advantage of substantial reductions 
in overtreatment with antibiotics and improved partner management.  
Conclusions: Using POC tests to diagnose chlamydia during antenatal care in sub-Saharan Africa 
entails greater health benefits than syndromic management does – and at acceptable costs – 
especially when restricted to younger women. Changes in diagnostic strategy and treatment regimens 
may improve people’s health and even reduce health care budgets. 
 
   4
Introduction 
There has long been a consensus that simple, affordable and preferably on-site tests are needed to 
improve the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections in the 
developing world.[1] Major progress has recently been made, and several tests are now on the 
market. We have conducted an economic evaluation to compare testing symptomatic and 
asymptomatic attendees using rapid point-of-care tests with the existing syndromic management of 
chlamydia. The setting for our analysis is the first antenatal care visit of pregnant women in 
Botswana. The antenatal care program in this country is well functioning and highly attended. We 
chose to focus on chlamydia, which is more common than gonorrhoea in this population, but the 
model can be adapted to the economic evaluation of the management of other sexually transmitted 
infections such as gonorrhoea and trichomoniasis.  
 
SEXUALLY TRANSMITTED INFECTIONS IN THE DEVELOPING WORLD 
Sexually transmitted infections (STIs) are highly prevalent in the developing world. An estimated 
340 million new curable STIs occur annually worldwide, of which almost half are chlamydia and 
gonorrhoea infections.[2] Sub-Saharan Africa has the highest worldwide prevalence of these two 
infections, which are major causes of morbidity, particularly in women.[3] In females, a cervical 
infection with N gonorrhoeae or C trachomatis can cause acute symptoms with increased discharge, 
dysuria and lower abdominal pain, or be asymptomatic. The infection can progress to pelvic 
inflammatory disease, which in turn may cause chronic pelvic pain, ectopic pregnancy and infertility. 
 
For pregnant women and their offspring, there is a risk of additional complications: intrauterine 
growth retardation, pre-term birth, perinatal morbidity and mortality, and postpartum upper genital 
tract infections.[4]   5
The advent and increase of HIV infection has further highlighted the importance of STIs as a 
major problem. Epidemiological and biological studies have shown that ulcerative and non-ulcerative 
STIs can enhance HIV transmission.[5, 6] Consequently, UNAIDS and WHO have recommended 
that high priority be given to the development of STI control programmes, one of the most important 
interventions for curbing the spread of AIDS.[7, 8] To explore cost-effective alternatives or additions 
to existing STI strategies is therefore of high relevance to health policy at both national and 
international levels.  
 
CHLAMYDIA AND GONORRHOEA IN THE CURRENT STI MANAGEMENT 
Due to the complications associated with maternal, foetal, and infant morbidity and mortality, it 
should be part of the mandate of the antenatal care programs to diagnose and treat chlamydia and 
gonorrhoea. However, diagnosis and treatment of STIs in the developing world is usually limited to 
the ‘syndromic approach’. In the early 1990s, the World Health Organization developed syndromic 
management guidelines for symptomatic STI patients for countries without laboratory support. With 
the use of flowcharts, presenting symptoms and clinical signs are classified into defined STI 
syndromes such as genital ulcer or genital discharge syndrome. The patients are treated with 
standardized drug regimens including at least two antibiotics - to cover the possible causes of their 
syndrome.[9] The vaginal discharge syndrome algorithm for the management of vaginal and cervical 
infections is far from ideal, and for chlamydia or gonorrhea, this simplified approach is neither 
sensitive nor specific.[4, 10-12] The low sensitivity hampers the possibility of preventing 
reproductive complications and sequelae and of interrupting onward transmission. The majority of 
women with a cervical infection are asymptomatic and will not be identified and treated with a 
syndromic approach.[13] Evidence from the Rakai, Uganda study on STI control for AIDS   6
prevention has shown that relying on treatment of only those with symptoms reaches less than 8% of 
the infected population.[14]   
The low specificity results in high levels of overtreatment, which increases drug costs and the 
risk of drug resistance, while patients unnecessarily experience side effects of drugs and changes in 
endogenous flora. A study from Zimbabwe indicates that about two thirds of patient with signs 
interpreted at clinic level as an STI are not infected and should not have been treated.[15] A high 
level of overdiagnosis undermines partner notification as most patients do not have an STI and their 
partners should neither be notified nor treated. Again, overtreatment of partners is costly to the health 
care system and the individual, and women may unnecessary be at risk of stigma and violence from 
their sexual partners when they refer them for treatment.[16, 17]  
  In Botswana, women complaining of symptoms of vaginal discharge or lower abdominal pain 
are managed with the vaginal discharge algorithm according to national syndromic approach 
guidelines.[18] Based on a risk assessment and the signs found on clinical examination, the women 
receive treatment for chlamydia and gonorrhoea and/or trichomoniasis and bacterial vaginosis and/or 
candidiasis. The syndromic approach is based exclusively on symptoms and clinical criteria, and the 
strategy relies heavily on the quality of care provided. It is a recognized problem in the routine care 
that STI patients quite often are assessed improperly. A national evaluation of the quality of the STI 
management in Botswana indicated that only a minority (17%) of the patients were assessed and 
managed according to the guidelines.[19] The lack of access to specific diagnostic tests and the 
uncertainties of the syndromic approach may discourage health workers from following the 
guidelines, resulting in inadequate history-taking and examination, insufficient or unnecessary 
prescriptions and partner notification without commitment.    7
The literature discusses alternative approaches to chlamydia and gonorrhoea in developing 
countries, such as risk assessment, clinical screening and mass treatment.[20, 21] The two former 
methods have low sensitivity and specificity; the latter is linked to development of antibiotic 
resistance and high drug wastage. The development of simple point-of-care tests for C trachomatis 
and N gonorrhoeae has been a high priority since the 1990s.[20, 22, 23] The continued use of the 
syndromic approach in the management of cervicitis has been viewed as a temporary solution for 
health care providers awaiting the availability of such tests.[23] 
 
INTRODUCING TESTS TO DIAGNOSE CHLAMYDIA    
The use of nucleic acid amplification tests (NAATs), the best diagnostic tool for C trachomatis 
infections, has long been a natural and established routine in the developed world. The tests are 
widely used both for testing symptomatic patients and screening for infections in selected 
populations, but they are costly and have been beyond reach for laboratories in resource poor 
settings.  
STI control programmes which take into account the prevalence of asymptomatic infections 
are also needed in developing countries.[7, 22, 24] Major progress in the development of point-of-
care tests has recently been made, and several tests are now on the market.[11, 25]
 The sensitivity and 
specificity of these tests will necessarily be lower than for the advanced, laboratory-based diagnostic 
tests. The Sexually Transmitted Diseases Diagnostics Initiative at the WHO has started a programme 
to evaluate simple, affordable point-of-care tests, and several are currently being field tested.[25] 
(http://www.who.int/std_diagnostics). So far, test evaluations have shown variable sensitivities (25-
85%), but high specificity (>90%).[26] A recent study found that a commercially available test which   8
is widely used in China had a sensitivity of 50%. More tests are in development, and most likely, 
more sensitive tests will be available within a few years. 
A rapid test with a sensitivity of 65% can lead to a greater proportion of infected patients 
treated compared to NAATs with sensitivity of 90% when the return rate for test results and 
treatment is low.[27] Mathematical models show that rapid tests with a sensitivity of 70% have the 
potential to reduce the prevalence of chlamydia and gonorrhoea in sex workers and avert HIV 
infections in their clients. Encouraging data on an improved rapid test for ocular chlamydial infection 
have recently been published.[28] The evaluated test had a sensitivity of 84% and a specificity of 
99% using PCR as the reference standard. 
 
POINT-OF-CARE TESTS IN ANTENATAL CARE IN BOTSWANA 
Botswana is one of the Sub-Saharan countries with high prevalence rates of HIV and STIs. In 2005, 
33% of the antenatal care attendees were HIV infected.[29] STIs are a major public health problem: 
during the last decade, between 100 000 and 200 000 STI-related outpatient consultations were 
registered every year.[30, 31] Among pregnant women in the capital of Botswana, Gaborone, 8% 
were found to have chlamydia, while 3% had gonorrhoeae.[32]   
To explore diagnostic tests as an alternative or addition to the current STI management is 
consistent with the health policy in Botswana.[33] Although resources are limited, Botswana is one 
of the few African countries classified as “Upper Middle Income”.[34]  Point-of-care tests for 
chlamydia can prove to be cost saving in a wider perspective, but health authorties may be 
discouraged by the direct cost of purchasing and using the tests. This is why using Botswana to 
evaluate the existing STI management and explore the costs and benefits of laboratory analysis in 
diagnosing STIs is favourable. STI and HIV prevalences are high, creating an obvious need to   9
improve the diagnosis and treatment of chlamydia,[35] and there is a realistic economic possibility to 
introduce this service. A research project on point-of-care tests in Botswana can be used as a model, 
providing likely short or long term benefits for other countries in the region. 
Among different relevant patient groups we have chosen antenatal care attendees to explore 
the costs and effects of introducing point-of-care tests because among pregnant women there is the 
added possibility of preventing the adverse obstetric outcomes related to these infections during 
pregnancy. There is also a logistic advantage of introducing an extra service to a relatively well-
functioning antenatal care program. The attendees meet at the clinic routinely; a good framework for 
diagnosis, treatment and follow-up. Screening for syphilis and HIV is already incorporated into the 
antenatal routine. At the women’s first antenatal visit, blood is drawn for Hb, blood group, RH-
factor, syphilis and HIV tests. The samples are either tested on-site or transported to a laboratory.  
In addition to the syndromic management of symptomatic pregnant women, all antenatal care 
attendees in Botswana are clinically screened for reproductive tract infections. The antenatal care 
guidelines recommend a routine speculum examination at the first antenatal visit, to “exclude genital 
infections, abnormalities and pelvic tumours”.[36]. It is not uncommon for abnormal vaginal 
discharge to be found in women not eliciting symptoms. As the nurses will not ignore pathological 
findings, asymptomatic women with signs of vaginal discharge are provided with syndromic 
treatment. This management bypasses the original entry point of the syndromic algorithms: 
symptoms which lead to health-care seeking. Specimens for the test can be taken at the genital 
examination at the first visit, the test can be analysed on-site and treatment provided if necessary. 
Thus, an introduction of point-of-care tests for chlamydia will not lead to any change in the number 
or content of the routine antenatal care visits.   10
In the process of implementing the prevention of mother-to-child-transmission (PMTCT) 
programme, and subsequently the antiretroviral treatment programme, the laboratory capacity in 
Botswana has been extensively upgraded to manage routine and clinical HIV testing, monitor the 
epidemic and perform research. In addition, all health posts and clinics have a lay counselor who 
performs point-of-care tests for HIV. To utilize clinicians or lay counselors to perform simple rapid 
tests for chlamydia could provide an opportunity to reduce the disease burden of this infection.   
Improved diagnosis of chlamydia in pregnancy is arguably an equitable health investment. In 
most countries in Sub-Saharan Africa, the antenatal care coverage is above 70%.[37] In Botswana, at 
least 95% of pregnant women attend antenatal clinics at least once during their pregnancy.[38]. 
Investing in a service that aims to cover all reproductive women and subsequently their partners and 
their children promotes a high degree of fairness in resource distribution. 
 
AGE AS A RISK FACTOR FOR CHLAMYDIA 
Youth is the single factor most strongly associated with C trachomatis infection among pregnant 
women in Botswana [35], which is consistent with established knowledge on STI epidemiology.[10, 
39] The patients’ age is already used in the diagnosis of chlamydia in the syndromic management: 
the risk assessment incorporated in the vaginal discharge syndrome is considered positive if the 
patient is under 21 years. If POC tests are introduced, age can be useful as a screening tool in the 
traditional sense, to minimize the number of standard diagnostic tests by identifying people with a 
higher-than-average prevalence of infection.[40] Chlamydia screening programs in other countries 
select people for testing based on their age, and we have evaluated whether this is a recommendable 
option in Botswana. 
   11
TREATMENT OPTIONS FOR CHLAMYDIA IN PREGNANCY 
Efficacy, tolerance, compliance, and cost are factors to consider when preparing guidelines for 
antibiotic treatment of chlamydial infection. In the national guidelines in Botswana, doxycycline 100 
mg tablets twice daily for seven days is the drug of choice for both males and females. In pregnancy, 
erythromycin 500 mg tablets four times daily for seven days is recommended. Antenatal care 
attendees in Botswana diagnosed with the syndromic approach are prescribed multiple drug 
regimens that require many tablets to be administered correctly, which may reduce compliance. The 
erythromycin regimen is complex in itself, and compared to other treatment alternatives, 
erythromycin has a significantly higher level of gastrointestinal side effects, which frequently 
discourages patients from complying with the regimen and thereby reduces the cure rate.[41, 42] 
This may be especially problematic in women who experience pregnancy nausea. 
Several drugs can cure chlamydia infections, but if poor compliance is suspected, directly 
observed single-dose therapy should be considered.[43]  The oral administration of 1 g of 
azitromycin has a similar or higher efficacy and similar or fewer side effects than the week-long 
regimens, and has become the drug of choice in most of the developed world.[44, 45] Clinical 
experience and research data suggest that azitromycin is effective and safe for the foetus[42] The 
azithromycin regimen is less costly than erythromycin. We have evaluated the changes in costs and 
effectiveness of a shift from the erythromycin regimen to azithromycin for the treatment of 
chlamydia infections in antenatal care attendees in Botswana. As doxycycline is a cheap drug with 
acceptable cure rates, we modelled doxycycline treatment to partners. 
 
PARTNER NOTIFICATION AND TREATMENT   12
The management and treatment of sexual partners of patients with treatable sexually transmitted 
diseases is essential to prevent reinfection of the index patient, cure infected partners, break the chain 
of transmission, and prevent complications[16] The evidence for the effectiveness of strategies for 
partner notification has been reviewed, but only 2 of 11 studies included were from developing 
countries.[46] The probability of reinfection is lowest if patient and partner are treated at the same 
time and avoid sexual intercourse during the following week. Botswana, as most low-income 
countries, uses a patient-based partner notification strategy: the index patients are told to inform their 
own contacts and refer them for treatment. 
With respect to treatment of partners, one can distinguish between epidemiological treatment, 
where all partners are empirically treated, and test-based treatment, where all partners are tested and 
those with a positive test are treated. The syndromic management relies on epidemiological 
treatment, and we also modelled epidemiological treatment for the point-of-care test strategy.  
 
ECONOMIC EVALUATIONS 
The health challenges facing sub-Saharan Africa are immense, and the discrepancy between needs 
and resource availability is striking. The HIV/AIDS pandemic represents the highest burden of 
disease, in particular among young children and adults in reproductive age. In Botswana, the life 
expectancy has fallen drastically the last decade; according to the WHO to 40 years.[47] The 
morbidity related to HIV is a great challenge for the health care system, which itself is struggling 
with the loss of manpower. Given the limited availability of resources, it is necessary to ask questions 
about their most efficient use.[48] Is this particular expenditure of health resources worthwhile, given 
the alternative uses to which they might be put? Budgets are insufficient to meet all health care 
needs, and decision makers need to choose which interventions should be publicly funded. Economic   13
evaluations could prove helpful in prioritizing between the ranges of competing health interventions 
in resource-poor settings.  
In all societies – from the richest to the poorest – there is a gap between what health care 
could achieve with respect to reduced mortality and morbidity, and what in reality is achieved. The 
reason is simply that societies have limited resources in terms of skilled manpower, equipment, 
buildings, pharmaceuticals, etc. Rationing of resources is therefore inevitable. In market-based health 
care systems, this is achieved by means of charging a market price for health care services such that 
there is a balance between supply and demand. This mechanism removes queuing and the impression 
that rationing is going on. Priority setting is achieved by the consumers’ willingness to pay. This 
willingness is captured by the prices, and the prices send signals to suppliers about what products are 
valued by the consumers. Most societies, however, have chosen to abolish free-market health care 
and introduced public insurance systems or other means such that people are not denied health care 
for economic reasons. Such health care systems tend to result in more equitable distribution of health 
care services, but will inevitably result in queuing because demand is not constrained sufficiently by 
user charges. While priority setting is achieved by the “the invisible market hand” in competitive 
markets, priorities are set by politicians or managers in public systems. Economic evaluation is a 
means to mimic the market mechanism by estimating benefits and resource use of different policy 
options.  
A full economic evaluation can be defined as “the comparative analysis of alternative courses 
of action in terms of both their costs and consequences”.[49] Economic evaluation is a tool for 
making decisions that will maximise for example health benefit. The basic tasks of any economic 
evaluation are therefore to identify, measure, value and compare costs and consequences of the 
alternatives being considered in an incremental analysis, which means that the difference in costs is   14
compared with the difference in consequences[49]Full economic evaluations are often classified into 
three different approaches: Cost-Benefit Analysis (CBA), Cost-Effectiveness Analysis (CEA) and 
Cost-Utility Analysis (CUA). In short, these methods are primary distinguished according to how the 
consequences are being measured.  
This evaluation of C trachomatis infection policies is a cost-effectiveness analysis (CEA), an 
analysis in which the health benefit is measured in natural units such as life year gained, hip fracture 
avoided, etc. In our case we use cured cases of chlamydia as the measure of benefit. The CEA (along 
with CUA) are dependent on comparisons to an external standard to assess whether a specific 
programme is worthwhile or not, because the goal for the decision-maker is to maximize the benefits 
within a given budget. The most comprehensive use of cost-effectiveness ratio is to analyse the 
incremental cost-effectiveness ration (ICER), which is the ratio between the difference in cost and the 









The cost analysis in a CEA is dependent on which perspective is chosen for the analysis. Analysis 
performed from a societal perspective is often preferred, which means that all costs and health 
consequences should be captured irrespective of who pays or who benefits. The costs included in 
such a perspective are all relevant resources consumed by implementing the relevant health care 
programme, and can be divided into the following cost items: health sector costs; costs on other 
(public) sectors; patient/family (time) costs and productivity losses. After identifying the relevant 
costs, the cost analysis consists of measuring the quantities of resources used and valuing them by 
assigning unit costs or prices. The final cost of the health care programme is then measured in 
monetary units. Due to lack of information on costs outside the health care sector, this analysis 
adopted a health care provider’s perspective.   15
Economic decision analysis is a systematic approach to decision making under uncertainty. 
The process is designed to help decision makers think clearly about the many elements of complex 
decisions, as in our case the range of possible consequences of introducing, or not introducing point-
of-care tests to diagnose chlamydia. The aim of a decision analysis is to synthesize currently 
available evidence regarding the effectiveness and costs of alternative health care strategies. The 
method is suited to incorporating into the decision-making process both what is known about a 
problem and also what is uncertain. In some instances the method will illuminate where better data 
are needed before a health-care decision can be made.   
 
WHAT IS ALREADY KNOWN ON THIS SUBJECT 
Genital chlamydia is the most common bacterial STI in Europe and the United States, and numerous 
cost-effectiveness analyses on screening for chlamydia in this setting have been published. In brief, 
screening with specific tests is shown to be cost-effective above a certain prevalence level in these 
countries. Studies that have included the management of partners have shown that effective partner 
referral is essential for a cost-effective screening program.  
The results from these analyses are not easily transferable to resource poor settings for a 
number of reasons. Disease patterns in general, the prevalences of STIs and HIV and the occurrence 
of complications are different, as is the health care systems and people’s beliefs and behaviors. More 
specifically, existing cost evaluations analyze the use of laboratory tests with high sensitivity and 
specificity which are too resource demanding for developing countries. There are only a few 
economic evaluations of chlamydia screening among pregnant women, and no published studies on 
chlamydia screening among pregnant women in developing countries. In conclusion, there is an 
obvious lack of economic evaluation to support the choice of strategy to manage C trachomatis   16
infections during antenatal care, particularly with regard to developing countries. The results from 
existing cost evaluations and important review articles are summarized below. 
 
From static to dynamic modelling 
The majority of published cost-effectiveness analyses are based on static models, commonly a 
decision analysis model. The static models of chlamydia screening focus on the disease and the 
disease progression in infected individuals. The effect measured will be number of infections 
detected and cured and complications avoided in these individuals. The models are referred to as 
‘static’ because they assume a constant force of infection.  
In 2000, the first dynamic models of chlamydia screening were published.[50, 51] C 
trachomatis is a sexually transmitted microbe, and transmission ‘dynamic’ models of chlamydia 
screening (such as the stochastic network simulation model and the state transmission simulation 
model) focus on the occurrence and spread of the infection in the population. The use of dynamic 
models has been advocated in the evaluation of large-scale screening programs, as these models 
incorporate transmission dynamics, re-infection and the change of disease prevalence over time.  
Programs targeting smaller groups such as pregnant women have been specifically mentioned as an 
exception, as they are less likely to lower the chlamydia prevalence.[52] Thus, there is a role for both 
static and dynamic models in the evaluation of C trachomatis screening programs.[53] 
Dynamic models require much more detailed data about the sexual behaviour and the 
infectious disease than static models, such as duration of partnerships, frequency of sexual 
intercourse and transmission probability per sexual contact. The uncertainties regarding the 
additional data needed for a dynamic model can be substantial. The main advantage of a dynamic 
model is that it incorporates the effects of changes in disease prevalence over time. Welte et al.   17
compare a static and a dynamic cost evaluation of opportunistic chlamydia screening in the 
Netherlands.[54] The static model estimated a cost-effectiveness of US$700 per major outcome 
averted, whereas the dynamic model rendered net savings. The models also differed in results 
regarding screening older women. The diverging outcomes of the model analyses were mainly 
caused by the transmission chains considered in the models and assumptions about the screening 
program’s influence on chlamydia prevalence and force of infection. A dynamic model accounts for 
the direct effects on the cured persons and the indirect protection effects on other persons. The static 
model mainly focuses on the savings resulting from prevented sequelae in the screened woman. As it 
assumes a constant prevalence, the model overestimates the cost-effectiveness ratio of an effective 
screening program that reduces the chlamydia prevalence.  
 
Cost-effectiveness of partner pharmacotherapy 
Some years ago, the risk for reinfection due to failed partner referral was included in the commonly 
used decision analysis.[52] Postma et al. found that within the broader framework of the screening 
program, partner pharmacotherapy was a cost-saving activity; primarily due to prevention of 
reinfection in women who have been cured through the screening.[55]  
 
Studies on cost-effectiveness of screening for chlamydia in pregnancy 
Screening sexually active women for chlamydia will result in averted costs of managing acute and 
long-term complications. For pregnant women, potential benefits of averted vertical transmission and 
post partum infections are relevant for every case of infection detected. We have identified two 
published cost evaluations of chlamydia screening specific for pregnant women (Appendix 1). Both   18
papers present static cost-effective decision models of chlamydia screening in pregnancy in which 
major outcomes averted is used as outcomes.  
A Dutch study concludes that screening with advanced laboratory methods for asymptomatic 
C trachomatis infection in pregnant Dutch women renders net savings at a minimum prevalence rate 
of 4% or more.[52] Nettleman and Bell have analyzed culture and direct antigen testing of pregnant 
women assuming different prevalences of infection and deriving probabilities of major outcomes 
averted from published literature. They conclude that screening all pregnant women is not cost-
effective, but the excess cost was modest when direct antigen tests were used.[56] 
Two papers present analyses that use a study population of pregnant women, but due to the 
use of short term outcomes (cost per infection detected), they are not strictly defined to case finding 
in pregnancy. Rours et al. discuss testing strategies with advanced technology and Hueston and 
Lenhart discuss different treatment regimen. [57, 58] We have identified no published economic 
evaluations of chlamydia infection in pregnancy that use dynamic models, none which include 
partner treatment and none conducted in resource poor settings. 
 
Economic evaluations for developing countries 
There is an obvious lack of cost evaluations of strategies to diagnose and treat sexually transmitted 
diseases other than HIV in developing countries. The papers identified by searches in Medline and 
EMBASE examine costs and benefits of the syndromic management, mass treatment, or management 
of STI patients in pharmacies (Appendix 2). One recent publication estimates the incremental cost-
effectiveness of using point-of-care tests compared to syndromic management of chlamydia and 
gonorrhoea among female sex workers in Benin.[26] It was assumed in the model that cervical 
infections increase the risk of HIV transmission 2-8 times. POC tests for chlamydia and gonorrhoea   19
with higher sensitivity than the syndromic approach could thus result in more cervical infections 
treated and reduce HIV transmission. The conclusion from this specific population was that such tests 
can be a cost effective strategy; averting HIV infections and decreasing the degree of inappropriate 
treatment of cervical infections.  
In general, diagnosing and treating STIs in developing countries have been considered cost-
effective.[59] The
 fact that bacterial and viral STIs can enhance HIV transmission is believed to 
increase the cost-effectiveness of STI management in countries with a substantial HIV prevalence. 
STI management has compared favorably with other interventions, for example highly active anti-
retroviral therapy (HAART).[60] Gilson et al. reported that improved management of STIs in rural 
Tanzania reduced HIV transmission by 40% at an estimated cost of $10 per disability adjusted life 
year (DALY) saved.[61] 
 
Reviews of economic evaluations of chlamydia screening 
The most recent systematic review of screening for C trachomatis identified 713 papers, and included 
57 formal economic evaluations and two cost studies - none from developing countries.[62] The 
authors conclude that three main methodological issues threaten the validity of the economic 
evaluations. Firstly, most evaluations, also of large-scale screening programs, used a static and not 
dynamic modeling approach that the reviewers consider inappropriate for the study of infectious 
diseases. Secondly, restricted outcomes such as cost per case detected should not be used as a basis 
for policy recommendations. Thirdly, most studies did not acknowledge or investigate the uncertainty 
associated with probability estimates for the long-term sequelae associated with chlamydia infection.  
  A review from 2002 assessed cost effectiveness of screening asymptomatic sexually active 
women less than 30 years of age in a primary care setting.[63] None of the evaluated studies were   20
from developing countries. The models showed screening to be cost effective at prevalences of 3-
10% and cost saving at prevalences as low as 1% if age was used as a selection factor and DNA 
based tests were used in urine samples. The authors emphasize that the assumptions used in the 
models have been difficult to confirm and there is a need for more data, particularly on the risk of 
complications in women with asymptomatic lower tract infection. 
  Another review of economic evaluations of chlamydia screening programs in developing 
countries concluded that studies show considerable variability with regard to end points (cost per 
case, per cured patient, per PID or major outcome averted), as well as the probabilities used for 
progression of disease, the considered sequelae and costing (e.g. cost per PID).[52] Most of the 
included studies identified were static models of screening among non-pregnant females seeking 
health care. All studies showed that chlamydia prevalence is one of the most important determinants 
of the cost-effectiveness ratio, and several studies showed that effective partner referral is essential 
for a cost-effective screening program. It was noted by the authors that no quality of life changes 
associated with chlamydia screening programs have been considered in the evaluations, and that not 
all chlamydia-associated diseases are taken into account (e.g. stillbirth, preterm delivery and low 
birth weight). 
We also identified a review of literature on the epidemiology of chlamydia infection, its 
health consequences, and the benefits, problems and cost-effectiveness associated with chlamydia 
screening with advanced laboratory tests among young women in the United States.[64] The authors 
report that the reviewed economic studies conclude that universal screening is more cost-beneficial 
than selective screening when the disease prevalence is above 2 to 10%. 
 
CHALLENGES WITH THE ECONOMIC EVALUATION IN THIS STUDY   21
The benefits of a health service can be classified as in the box below: 
 
 
1. Health consequences 
a)  Reduced morbidity and complications 
b)  Reduced mortality 
 
2. Economic consequences 
a)  Direct benefits: saved future health care costs  
b)  Indirect benefits: improved future working capacity  
c)  The value of less personal pain and loss 
 
 
Major challenges in performing a cost-effectiveness analysis of the management of STIs in 
developing countries lie in the estimated effectiveness. Some of the complications caused by C 
trachomatis are immediate, whilst the majority occur after a long time and will be difficult to 
measure. In addition, complications such as pelvic inflammatory disease, extrauterine pregnancy, 
premature labour and the neonatal infections can occur both because of and independent of 
chlamydia. In Botswana, as in most developing countries, estimates of the occurrence of these 
conditions are largely unavailable. If any information exists, the proportion of the conditions that 
may be attributed to chlamydia is unknown.  
  To compare the cost effectiveness of chlamydia management strategies with other health 
interventions, the effectiveness has to be measured in a value such as quality adjusted life years. The 
difficulty with estimating the chlamydia-associated diseases makes it impossible to consider quality 
of life changes associated with chlamydia management programs.  
The costs to the health services in sub-Saharan Africa of a given complication of STIs are 
also nearly impossible to estimate. In Botswana, the public health sector operates with overall lump 
sums, for example salaries or drug use in primary health care. There are no separate budgets at 
hospitals and clinics or for specific programs such as antenatal care, and the cost of, for example, a 
hospital stay or specific diagnostic or treatment procedures have never been calculated.   22
We selected a static model to evaluate the introduction of point-of-care tests in antenatal care. 
A dynamic model requires much more detailed data about the sexual behaviour and the natural 
history of C trachomatis infections. The exact patterns of sexual behaviour in a population are 
virtually impossible to assess. What is the nature of the formation and termination of steady and 
casual partnerships? What is the spread of infection in partnerships? In our study, the majority of the 
pregnant women stated when interviewed that they had one partner during the last 12 months. On the 
other hand, the prevalences of sexually transmitted infections were high (chlamydia 8%, gonorrhoea 
3%, trichomoniasis 19% and syphilis 5%). In this setting we question whether a dynamic model 
would perform better than a static model, as the additional data needed would be either unreliable 
estimates or “educated guesses”.  
 
AIMS AND HYPOTHESIS 
The aim of this economic evaluation was to compare the costs and health consequences in sub-
Saharan Africa of testing asymptomatic and symptomatic women with a POC test versus syndromic 
management of chlamydia in antenatal care. Two treatment alternatives in pregnancy were evaluated: 
erythromycin and azithromycin, while we modelled doxycycline to partners. Three alternative 
strategies were evaluated: managing all women, selective management of women under 30, and 
selective management of women less than 20 years.  
 
Methods 
We evaluated the cost and the effectiveness of syndromic approach and point-of-care tests in 
diagnosing and treating chlamydia infections in antenatal care. In a static decision model comparing 
the two strategies, we incorporated the evaluation of three management strategies: managing all   23
women, selective management of women under 30, and selective management of women less than 20 
years. Two treatment options were evaluated, the current erythromycin regimen and azithromycin 
provided directly observed. Core issues in the economic evaluation are summarized in Table 1. 
 
 
THE DECISION ANALYTIC MODEL 
A decision tree incorporating the two strategies for the diagnosis and treatment of chlamydia among 
antenatal care attendees was conducted in TreeAge Pro Suite 2006. The decision tree is a branching 
structure in which nodes symbolise voluntary decisions and events which have multiple possible 
outcomes and are not under the decision maker’s control. The node’s branches represent the 
alternatives or outcomes associated with that event (Figure 1). We modelled all main event pathways 
that had distinct resource implications or outcome values associated with them. The probabilities of 
the different outcomes, the resource consequences and the health consequences associated with the 
diagnostic strategies were estimated.  
The risk of reinfection due to failed partner referral was included in the model. In our study 
among antenatal care attendees, 671 (95%) of 703 women reported one partner during the last 12 
months. We therefore assume that the women have, as a median, one partner with whom she will be 
sexually active during the current pregnancy. We have not included further transmission from the 
male partner. We are aware that multiple partnerships are common in Botswan.[37] This and the high 
prevalences of STIs among the antenatal care attendees make us believe that modelling a steady 
couple may not represent the full reality. If the pregnant women or her partner has more than one 
partner, the effect of correctly diagnosing and treating chlamydia is underestimated.  
Information to feed the decision tree was based on our cross-sectional study among 703 antenatal 
care attendees who visited 13 primary health care clinics in Gaborone, the capital of Botswana, 
between October 2000 and February 2001 and/or  literature reviews and/or expert opinions. The   24
study is described in Appendix 3, the literature reviews are described in Appendix 4.  
The literature reviews for the costs and probabilities consisted of extensive searches in 
Medline, Embase, The Cochrane Library, text books, reports and other relavant sources, including 
local literature searches. The reviews do not formally qualify for categorization as systematic; it was 
practically impossible to do formal reviews for all the parameters in the model with such detail.  
The expert panel consisted of six medical doctors with wide clinical, administrative and 
research experience from the field: Three participants are medical doctors and representatives from 
Department of HIV/AIDS Prevention and Care in the Ministry of Health, including one former and 
one current leader of the STI management in Botswana. These two have supervised nurses and run 
workshops in syndromic management nationwide, providing them with a unique knowledge of the 
challenges of the syndromic approach from the nurses’ perspective and experience. Three 
participants are Norwegian medical doctors with extensive experience with research in the field of 
STIs and reproductive health in sub-Saharan Africa. Issues discussed in the expert panel were also 
discussed with nurses in the primary health care in Botswana and with other resource persons in the 
country. 
The key structure of the decision tree is shown as one main tree and three partner subtrees 
(Figure 1). The first step in the model represents the choice of chlamydia management for the women 
coming for their first antenatal care consultation. The structure of the decision tree is identical for the 
two strategies, but the probabilities of the events are different. If we use the syndromic management 
as an example, the next node in the model is the probability of having symptoms or signs which 
results in a diagnosis or not. Symptoms and signs are not specific of C trachomatis infection, and the 
next nodes in the decision tree represent the probability of infection among the women who have 
(true positive) and the women who have not (false negative) been syndromically diagnosed with   25
chlamydia. All these probabilities are based on data from our epidemiological study on the 
prevalence of selected STIs among pregnant women in Gaborone. The following nodes include the 
probability of being prescribed correct treatment, the patient being compliant with the treatment 
regimen and the treatment being effective.  
Partner notification and treatment is shown in the partner subtrees. Some partners are, while 
others are not, infected. The partners may or may not be notified and attend the clinic, they may or 
may not be prescribed correct treatment and they may or may not be compliant. Infected partners 
may be symptomatic or not, and symptomatic males may or may not seek care independent of their 
female partner, which may or may not be effective. Partner subtree A illustrates that for the women 
with C trachomatis infection who are correctly diagnosed and treated, it is important that the partner 
is treated to avoid reinfection. If partners are not cured, the female may be reinfected. As illustrated 
in partner subtree C, the situation is reversed when the infected female is not cured: infected partners 
who are treated adequately may be reinfected by their female partner. Partner subtree B illustrates 
partner notification of uninfected partners. 
The expert panel assumed that the probability of correct prescription by nurses; patients’ 
compliance to prescribed drugs; and partner notification will be higher if an antenatal care attendee is 
diagnosed with chlamydia using point-of-care tests than with syndromic management. When a 
pregnant woman is diagnosed with vaginal discharge syndrome, she may have candida, bacterial 
vaginosis, trichomoniasis, chlamydia or gonorrhoeae, or physiologically increased discharge or 
abdominal pain which is common in pregnancy. The treatment for vaginal discharge syndrome 
includes a multiple and complex drug regimen, and both the nurses’ adherence to the treatment 
guidelines and patients’ compliance to this regimen is known to be low. As the condition most likely   26
may not be sexually transmitted, it is understandable that neither nurses nor patients are dedicated to 
ensure partner notification, not risking domestic disturbance unnecessarily. 
  All POC tests for chlamydia have high specificities, and thereby the advantages of a 
specific test, which the syndromic approach is lacking. A positive test requires the prescription of and 
compliance to one drug, and partner treatment is imperative. For the POC test strategy, there are no 
data on these events. The expert panel inflated the values used for the probabilities in the syndromic 
strategy, assuming that the additional confidence in the POC test result would improve management 
(Table 1). The possibility that this is not the case is covered by using large uncertainty bounds, 
including in the lower bound a value that represents syndromic management. The upper bound 
represents much better performance, as found in developed countries where specific chlamydia tests 
are in use. 
The analysis evaluate testing for C trachomatis only, assuming that tests for N gonorrhoeae 
infection, trichomoniasis, bacterial vaginosis and candida remains unavailable in the routine care. 
This implies that attendees with symptoms or signs of vaginal discharge or lower abdominal pain 
must be managed with syndromic approach algorithms for other conditions in addition to an adequate 
response to the chlamydia test. Asymptomatic attendees testing positive for chlamydia need treatment 
for this infection only. 
 
HEALTH OUTCOMES ASSOCIATED WITH TREATING CHLAMYDIA 
We sought information in Botswana on the prevalence of chlamydia related complications and the 
resources spent to treat these complications. Local experts such as medical doctors and nurses, health 
statisticians, health economists and officers in the ministry were interviewed, and health statistics on 
patient morbidity and mortality and national health accounts and health budgets was collected. The   27
effects of chlamydia on morbidity and mortality in Botswana have never been measured. We have 
not been able to identify any statistics or research which could have demonstrated the benefits of 
diagnosing and treating chlamydia (such as reduced number of complications and reduced infection 
transmission). We also conducted literature reviews on the complications of chlamydia in pregnant 
women and their related costs in other developing countries (Appendix 5). 
Ideally, we should have measured the prevented complications in chlamydia infected women 
and their offspring, and the resulting cost savings to the health system, with the different strategies. 
After extensive literature searches, interviews with experts and collection of health statistics, we 
conclude that we lack knowledge on consequences and long term complications of C trachomatis 
infection in Botswana and similar settings. The comparison of point-of-care tests and syndromic 
approach in the management of chlamydia is therefore restricted to measuring health outcome, or 
effectiveness, as the number of infections successfully treated and cured with each strategy. 
Discounting was not performed, as the time perspective was less than one year. 
 
MODEL INPUT PARAMETERS: THE FEMALE DECISION TREE 
All parameters have been given a base case value, with which the base case analysis is run. All 
probabilities also have upper and lower values, as the values could not be determined exactly. The 
range either represents the range between different studies on the topic (azitromycin cure rates), a 
95% confidence interval (CI) (sensitivity and specificity of syndromic approach) or a reasonable, 
subjective bound of uncertainty decided by the expert panel (probability of partner notification in the 
syndromic approach). The model input variables; the values and the basis for the ranges are shown in 
the embedded Table A1. 
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Chlamydia prevalence  
Chlamydia prevalence is based on data from our study among 703 antenatal care attendees in 
Gaborone, Botswana. In this population, young age was the factor most strongly associated with 
cervical infection (embedded Table A1 and A2). Based on this knowledge, we modelled different 
management strategies: to include all women, selective management of women under 30, and 
selective management of women less than 20 years. Chlamydia incidence is not included in the 
model. As prevalences may differ in other settings or change over time, we used broad uncertainty 
ranges to assess the effect of prevalence on the cost-effectiveness estimates in one-way sensitivity 
analysis. The prevalence range from 3-31% represents the range of prevalences found in other studies 
among antenatal care attendees in sub-Saharan Africa.[4] 
 
Table A1: Age specific prevalence of chlamydia among 703 antenatal care attendees in Gaborone, Botswana 








  8.1 (5.9-11-1) 
  3.1 (1.4-6.5) 
Total  703 (100)    7.5 (5.8-9.7) 
 
 
Table A2: Chlamydia prevalence in age groups suitable for selective management; from the study among 703 antenatal 
care attendees in Gaborone, Botswana 
Age  N (%)  % Prevalence (95% Confidence interval) 
<20 
<30 
  76 (10.6) 
508 (72.3) 
15.8 (9.3-25.6) 
  9.3 (7.0-12.1) 




Sensitivity and specificity of the point-of-care test  
Several POC tests for C trachomatis are commercially available. The evaluated specificity of the 
tests is consistently found to be high, whereas the sensitivity has not yet been firmly determined 
(Table B). The specificity of the test was therefore set at 98.5% (97.0-100%). 
The sensitivity has varied widely across tests and the population being tested, ranging from 25 
to 85% [65]. The evaluations have also differed with respect to reference standard used. A recent   29
publication presents an evaluation of an antigen detection assay widely used in China, finding a 
sensitivity of 50% [67]. As higher sensitivities are more ideal, more tests are in development. 
Recently, data on a rapid test with 83.6% sensitivity for ocular C trachomatis infections was 
published [28].  Introduction of a test with a sensitivity of at least 50% is a current option, and most 
likely, more sensitive tests will be available within the next few years. We therefore modelled a 
baseline sensitivity of the test of 50%, with a range from 50-85%. Tests with sensitivities lower than 
50% were not considered, as tests with lower sensitivity would detect fewer infections than the 
syndromic approach.  
 
Table B: Sensitivity and specificity of Chlamydia trachomatis point-of-care tests 
 
Point-of-care test  Patient group  Sensitivity  Specificity  Reference 
Antigen detection assay 
Chlamydia optical immunoassay  
Chlamydia optical immunoassay  
Chlamydia optical immunoassay  
Direct fluorescent antibody test 
IgA Rapid Sero Test (ELISA) 
“High risk women” 
Female STI clients 
“Female clients” 
Female STI clients 














Yin et al. 2006 [67] 
Pate et al. 1998 [68] 
Widjaja et al. 1999 [69] 
Swain et al. 2004 [70]  
Swain et al. 2004 [70] 
Witkin et al. 1997 [71]  
 
 
Sensitivity and specificity of syndromic management 
 
The sensitivity and specificity of the syndromic approach were based on our study data for new 
antenatal care attendees (Appendix 3). Pregnant women coming for their first antenatal care visit who 
complain of vaginal discharge or lower abdominal pain will be managed with the vaginal discharge 
algorithm. In addition, all attendees are clinically screened for STIs, and women with signs of 
cervical or yellow vaginal discharge will also be provided treatment. This strategy, in which 
symptoms and/or signs are used as entry points to the vaginal discharge algorithm, has a sensitivity of 
49% (95% CI 0.36-0.62) and a specificity of 65% (95% CI 0.61-0.69) in the diagnosis of chlamydia. 
 
Probability of drug being prescribed   30
The probability of nurses’ adherence to prescription guidelines for the syndromic diagnosis is also 
based on study data. Among 165 attendees who had been clinically diagnosed with chlamydia, 140 
(85%, 95% CI 79-90%) had been prescribed erythromycin.  This is consistent with other studies from 
sub-Saharan Africa (see box below).  
The probability of prescription of the recommended drug is likely to be higher if the specific 
point-of-care test is positive. The nurse will know the diagnosis, and if the attendee is asymptomatic, 
only one drug regimen is necessary. Numerous discussions with nurses in primary health clinics in 
Botswana revealed that the low rates of prescription in accordance with the treatment guidelines in 
syndromic approach are caused by the uncertainty in the diagnosis and the complexity of the 
treatment regimens. The nurses report using their own judgement and clinical experience to prescribe 
drugs for what they think is causing the patient’s symptoms or signs. Their knowledge of type and 
dosage of drugs to treat chlamydia, is high. Cost-effectiveness analyses of chlamydia screening from 
developed countries are all operating with 100% probability of prescription [52, 55]. A Medline 
search yielded no studies on health workers’ prescription of treatment for chlamydia specifically (see 
Appendix 4). The expert panel assumed that if a specific point-of-care test for chlamydia is positive, 
it is realistic to assume a 93% (85-100%) probability of prescription of treatment. The nurses may 
forget the prescription or prescribe ineffective drugs, it is likely that it happens in about one in 15 test 
positive cases.  
 
In a study from Botswana including 66 female STI clients who were diagnosed with vaginal discharge 
syndrome and 33 who were diagnosed with lower abdominal pain, health workers who were observed 
prescribed treatment for chlamydia to 92 (93%) of the clients [Boonstra et al. 2003]. This prescription rate 
is likely to be higher than in an antenatal care population. The probability of a chlamydia is higher, and 
with the lower abdominal pain syndrome, only drugs for chlamydia and gonorrhoea is recommended. Buve 
et al estimate (2001) in their report from Tanzania that 80% of the STI clients were prescribed adequate 
drugs.  
 
Compliance and drug effectiveness   31
When the correct drug has been prescribed, patient compliance, drug efficacy and treatment of 
infected partners are the main factors necessary for successful cure of chlamydia. It is generally 
accepted that the drugs recommended for chlamydia are nearly 100% effective when taken as 
recommended, and we have therefore used a combined probability for compliance and drug efficacy. 
The risk of reinfection is captured in a separate variable. 
 
Compliance and drug effectiveness with erythromycin  
•  Probability of cure with syndromic management = 0.50 (0.30-0.70) 
•  Probability of cure with point-of-care tests = 0.86 (0.50-0.95)  
Compliance and drug effectiveness with azitromycin  
•  Probability of cure with syndromic management = 0.95 (0.88-1.00) 
•  Probability of cure with point-of-care tests = 0.95 (0.88-1.00) 
 
The probability of cure with different treatment strategies is based on original studies and 
reviews, Appendix 6. We use a 0.95 probability of compliance and drug effectiveness for the single-
dose treatment with azitromycin, independent of diagnostic strategy [72]. The base case value and the 
uncertainty bounds are based on available original studies from developed as well as developing 
countries, and on review papers. The literature consistently shows that the compliance and drug 
effectiveness for the single dose treatment is very high, and to ensure high compliance, directly 
observed treatment can be introduced. Cure rates for erythromycin are lower, as the more complex 
treatment regimen and a greater occurrence of adverse effects reduce compliance [73, 74]. In original 
studies and reviews of cure rates with erythromycin where the chlamydia diagnosis is based on a 
specific test, the probabilities of cure were 0.86 (0.72-0.95). The expert panel believe that the cure 
rates for attendees diagnosed with a point-of-care test are likely to be similar, but assigned large 
uncertainty bounds (0.50-0.95).  
The 0.50 (0.30-0.70) probability of cure when erythromycin is prescribed to attendees 
diagnosed with syndromic approach is based on expert opinions and indirect data from our study 
among antenatal care attendees. Patients diagnosed with the vaginal discharge syndrome must   32
simultaneously administer up to four drug regimens correctly, and often don’t know what condition 
they are suffering from - both aspects obviously having an impact on compliance. In our study from 
Botswana, the prevalence of chlamydia was identical (7.5%) among women who had been prescribed 
erythromycin earlier in the current pregnancy, compared to women who had not. Low compliance 
was a core factor in explaining why the prescribing of erythromycin did not necessarily lead to a cure 
for C trachomatis. The attendees who in the study setting are syndromically diagnosed with a 
cervical infection have an insignificantly higher prevalence of chlamydia compared to those who 
have not been diagnosed. The expert panel also notes that their common clinical experience is a high 
level of non-adherence to erythromycin among women diagnosed with vaginal discharge syndrome. 
  
There are few papers published in Medline on patient compliance to STI drugs in developing countries (see 
Appendix 4). Only clinical cure rates can be measured in the syndromic management of STIs: As it is 
unknown which infection or condition the patient is suffering from, information on drug efficacy or 




MODEL INPUT PARAMETERS: THE PARTNER SUB-TREE 
 
 
Probability of partner being infected and probability of reinfection 
The of chlamydia transmission rates between pregnant women and their partners in sub-Saharan 
Africa is unexamined. The probability of the partner being infected, and a cured female or male being 
reinfected, is based on co-infection studies from the US, UK or Australia on patients in STI clinics 
and their steady and casual partners (Table C). The Medline search and the studies are described in 
Appendix 4. These studies are hampered by the lack of gold standard laboratory tests, by their 
inability to have included nearly all partners, and by the fact that both steady and casual partners are 
examined . The probability of transmission will vary from individual to individual and between 
subgroups, and the studies may therefore not necessarily be relevant to a population of antenatal care   33
attendees with steady partners in a developing country. The studies indicate that the transmission of 
chlamydia is equal and bidirectional between sexual partners [75]. It is also dependent on the number 
of sexual contacts in the couple, and thus higher among steady partners. The expert panel concluded 
that the transmission probability will be in the higher range (0.80), but we have used wide uncertainty 
bounds (0.50-0.96). The panel’s main arguments were a) The majority of the pregnant Batswana 
women in our study reported that they had one steady partner with whom they had had a relationship 
for one year or more, and b) The prevalences of other RTIs are very high in the area, most likely 
increasing the susceptibility and infectiousness of genital infections. In our study, 21 (3%) were 
infected with N gonorrhoea, T vaginalis was identified in 131 (19%) women, bacterial vaginosis in 
268 (38%) women and Candida species were identified by microscopy and/or culture in 416 (59%) 
of the women. Noteworthy, this is only a selection of conditions and not including any of the 
infections causing genital ulcer. 
We have not modelled possible chlamydia infections in partners of uninfected women. In 
addition, we assumed that none of the male partners who are effectively treated reinfect their female 
partner before they themselves are cured. 
  
Table C: Infection rates in partners of males and females with chlamydia 
Study population  Infection in  
♂partners 
Infection in  
♀partners 
Reference 
1. STI clinic, USA. 53 couples concordantly  
    infected; in 48 couples one was infected 
2. STI clinic, UK. 97 M and 93 F index cases, half of  
    their partners were tested 
3. STI clinic, UK.404 chlamydia-infected ♀ reported  
    632 sexual contacts and 147 (23%) were tested 
4. Australian study, primary health care and specialist 
























Probability of infected male being symptomatic   34
Economic evaluations of chlamydia screening which include partner notification and treatment, 
estimate that 30-50% of men with chlamydia infection are symptomatic. We have not found any 
original studies verifying this estimate; such data are virtually non-existing [79]. Studies among men 
seeking care overestimate the symptomatic/asymptomatic ratio, while population prevalence studies 
underestimate the ratio –as symptomatic men will have sought care and been treated. In a population-
based study from Uganda, 92% of men with chlamydia reported no symptoms during the last 6 
months [14]. In a work-site-based study from Tanzania, 89% of men with chlamydia reported no 
symptoms [80]. In a study among young incarcerated minority males in the US, 10% of men with 
chlamydia had symptoms [81]. Two population based studies on urethritis in men from Tanzania 
showed that 35% of men with chlamydia and/or gonorrhoea were symptomatic [79]. As gonorrhoea 
is more often symptomatic, this value is probably too high for chlamydia infections. Based on these 
data, we modelled that 0.15 (0.10-0.20) male partners are symptomatic. 
 
Probability of partner notification and health care attendance 
Many factors will influence if a partner is notified and attends a health care facility. The health care 
worker has to counsel the antenatal care attendee on partner notification, the woman has to notify her 
partner, and the partner has to attend a health facility. We have plausible estimations for overall 
partner attendance, but there are no data for and it is difficult to estimate partner attendance in detail 
for subgroups of antenatal care attendees (see Box below). We have therefore modelled a mean value 
for the probability of partner notification and attendance to a health facility for all partners of the 
diagnosed females.  
 
   35
 
Factors which may influence partner notification and/or attendance 
•  If the antenatal care is prescribed treatment or not 
(The nurse may be less likely to counsel on partner notification, and the antenatal care attendee may be 
less conscious regarding notification. On the other hand, women who are not prescribed correct 
treatment are often prescribed other, but inappropriate drugs, a situation which not necessarily will be 
associated with reduced partner notification). 
•  If the male partner is symptomatic or not 
(Symptomatic males may be more likely to attend a clinic when being notified by their partner. Or; 
symptomatic males may be less likely to attend a clinic when notified because he may have sought 
other care (independent care seeking is included in the model). 
•  If the male partner seek other care independently (mutual influence) 
 
The success of partner notification is dependent on whether the partners are steady or casual, 
whether the diagnosis is syndromic or specific, on the notification strategy applied, as well as the 
cultural setting. We use health statistics data from Botswana on partner notification within the 
syndromic approach. These data are in line with studies from other sub-Saharan countries on partner 
notification and attendance. There were 0.085 male STI contacts registered per female STI client in 
Botswana in 2002, demonstrating that partner notification is very poor [82].  The 91 738 registered 
STI syndromes among female clients do not include the STI syndromes diagnosed among the 
approximately 40 000 antenatal care attendees registered the same year. We do not know how many 
of the men who were referred by a pregnant partner, and thus lack direct data on the partner referral 
rate among pregnant women diagnosed with an STI. Two observational studies on STI management 
in Botswana report that advice on partner notification including the issuing of a contact slip was 
provided to 61% and 66% of the STI clients, respectively [83, 84].  Less than five minutes in total 
was spent per STI client, in a consultation which is meant to contain history taking, clinical 
examination, diagnosis, treatment and counselling. These data emphasize that the number of partners 
who will be notified by the women and subsequently attend a health facility is low. 
The lower bound of partner notification and attendance with the POC test strategy represents 
the current partner attendance, whereas we used data from studies in developed countries as a basis   36
for the upper bound (Table D). Medline searches and the studies identified are described in Appendix 
4. Many studies on partner notification are performed under optimal conditions, often with the aim of 
improving the partner management, and may not represent routine care. The participants in the expert 
panel have wide theoretical knowledge and clinical experience with partner notification in 
developing countries. They concluded that with the use of specific point-of-care tests, a realistic 
estimate of the probability of partner notification and attendance will be 25% (0.0.09-0.65%). 
 
Table D Partner notification and attendance to health facility:  
 
Partners  Studies used as a basis for the modelled probability  
Notified Attend 
Reference 
Syndromic management/African countries 
  Male partners per female STI client in Botswana 
  Female STI clients in Uganda. A study to improve partner notification. 
  Female STI clients in Uganda 
  STI clients in South Africa 
Diagnostic test/western countries 
  STI clients in the Netherlands. Optimal conditions. 






















Modelled probability of partner attendance 
  Syndromic approach strategy 
  Diagnostic test strategy 
                     8.5% (5-15%) 
                   50.0% (35-65%) 
 
 
Probability of symptomatic males seeking other care and being cured  
Symptomatic males may seek care independently of their pregnant partner, and they may 
subsequently be adequately managed or not.  Data on health care seeking among symptomatic males 
is scarce. Buve et al. has reported from Tanzania that 51% of males and females with genital 
discharge or genital ulcer sought care [79]. Importantly, how many of the partners who seek care 
after being notified by a partner and how many who seek care independently is not reported –and 
probably not known. In a population-based study in Botswana, of the male respondents who ever had 
STI symptoms, 85% had been to a public health facility (which may or may not be because he has   37
been notified by his partner), 26% had sought a traditional healer, 16% had been to the pharmacy and 
14% to a private doctor [37]. However, the number of symptomatic episodes among these males is 
not reported. In conclusion, data to estimate other health care seeking among symptomatic partners 
are very uncertain. The expert panel based their estimates on a) available studies, b) their common 
clinical experience (for example that many patients don’t seek health care before their symptoms are 
severe), c) knowledge of and literature on the wide use of alternative and traditional medicine in the 
population, and on discussions with nurses in the primary health care. Based on the limited data and 
on expert opinions, we estimate that 50% (30-70%) of the symptomatic males, who do not attend a 
health facility as a result of partner notification, seek the health services independently. 
The cure rates among these symptomatic males who seek health care is the sum of a correct 
diagnosis, a correct prescription, sufficient compliance and avoidance of reinfection. We lack 
accurate data from public clinics in sub-Saharan Africa on cure rates among males with urethral 
discharge. The described study by Buve et al. estimated cure among male STI clients: 63% were 
diagnosed correctly, 73% were prescribed correct treatment and 84% were compliant [79]. In an 
observational study from primary health care in Botswana, adequate history taking and clinical 
examination among male STI clients was found in 54% and 57% of the cases [83]. Of the males who 
- often on scanty evidence – were diagnosed with urethral discharge syndrome, 91% received an 
appropriate prescription. Compliance was not measured in this study, and the authors note that the 
nurses may perform better when being observed. We have not found any literature estimating cure 
rates of the management of patients with genital symptoms in private clinics, in pharmacies or among 
traditional or faith healers.  
The expert panel agreed that this is a parameter with a large degree of uncertainty, and 
estimated that 50% (30-70%) of the symptomatic males who seek care independently are cured for   38
their chlamydia infection.. They based their estimate on a) the limited data available, b) their 
knowledge of and experience from primary health care in Botswana and other sub-Saharan countries 
and c) on discussions with nurses in the primary health care and other resource persons. In the model 
we have not accounted for the fact that an infected male partner may notify his pregnant partner 
resulting in her treatment and cure.   
 
Probability of correct prescription 
The probability of correct prescription to male partners with the syndromic approach strategy is 
based on the two observational studies on syndromic management of STI clients in Botswana. In the 
first study among 33 males with urethral discharge, 70% were prescribed ceftriaxone for gonorrhoea 
and 76% were prescribed doxycycline for chlamydia [84]. In the second study, all 32 males with 
urethral discharge syndrome were prescribed ceftriaxone and doxycycline [83]. We have not 
identified studies on quality of prescription to partners, and we therefore assumed that the probability 
of correct prescription will be within the range of the identified studies of index patients (0.85, 0.76-
1.00).  
As discussed under the description of the parameters in the “female decision tree”, the expert 
panel assumed that the probability of correct prescription to male partners will be higher if a specific 
point-of-care test is positive than with the syndromic approach. Cost-effectiveness analyses of 
chlamydia screening from developed countries are all operating with 100% correct prescription. We 
base the upper bound of the probability of correct prescription with the test strategy on studies these 
cost evaluations [55]. The expert panel assumed that if a point-of-care test for chlamydia is positive, 
it is realistic with a 93% (85-100%) probability of prescription of treatment. The nurses may forget   39
the prescription or prescribe ineffective drugs, but it is likely that correct drug is prescribed to 14 of 
15 partners of test positive attendees. 
 
Probability of compliance and drug effectiveness among male partners 
In Botswana, the standard treatment for chlamydia in males is doxycycline 100 mg tablets twice daily 
in one week. We have also modelled directly observed treatment with 1g azitromycin, which may be 
considered to improve compliance to the treatment. 
It has been shown that full compliance to doxycycline may not be necessary to obtain a cure. 
We have not found useful data on compliance from developing countries, and we did not identify any 
studies on compliance and cure rates in partners. The probabilities used for the syndromic 
management strategy represents the experts opinion of the local conditions. The panel assumed that 
with the doxycycline regimen, partners of patients with a positive chlamydia test will be more 
compliant than partners of patients diagnosed with vaginal discharge syndrome. They will know that 
their partner had chlamydia and, for partners of asymptomatic attendees, only one drug regimen is 
necessary. The lower bound of the 0.90 (0.80-1.00) probability of compliance to and effectiveness of 
doxycycline with the point-of-care strategy is identical to the estimate of the current level, whereas 
the upper bound is based on original studies and reviews from developing countries. As data on 
compliance among symptomatic versus asymptomatic partners are lacking, we used the same 
probability of compliance and drug effectiveness for all male partners regardless of symptoms. 
 
 
RESOURCE CONSEQUENCES AND COST MEASURES 
Diagnosis and treatment of chlamydia in pregnancy takes place within the framework of the antenatal 
care services and the STI management program. For the syndromic management we modelled   40
treatment costs (C♀treatment), which include the direct drug costs (Cazithromycin or Cerytrhromycin) and the 
cost of a pharmacy technician at the clinic outlet dispensing and informing about the drugs (Δt in 
hours x Cstaff2). The modelled costs of partner treatment (C♂treatment) also include the direct drug costs 
(Cazithromycin or Cdoxycyclin) and the dispensing process.  
For the use of POC tests we also included the test costs (Ctest per test) and the cost of the extra 
time needed to undertake each test (Δt in hours x Cstaff1). Currently available point-of-care tests cost 
from US$ 0.85-7.00 [11, 26]. We evaluated direct test costs from US$0.5-4.0, as cheaper tests may 
be available in the near future. We did not include costs of training needs for the staff undertaking the 
test. Introducing the use of POC tests to diagnose chlamydia in pregnancy will benefit from two 
existing programmes: the antenatal care programme and the STI management programme. At the 
women’s first antenatal visit, they undergo a clinical examination , urine is checked with a dip-stick, 
and blood is drawn for Hb, blood group, RH-factor, syphilis and HIV test. Taking a specimen and 
performing the POC test can relatively easily be incorporated in this routine. Additionally, the 
syndromic approach has been the established management of STIs in sub-Saharan Africa for decades, 
and requires frequent training and supervision of health personnel. A shift in the diagnostic strategy 
of chlamydia in antenatal care fits well within the ongoing activities of the national STI management 
programmes. 
In the base case analysis, we used drug and salary costs from Botswana, while upper and 
lower ranges for the costs were estimated and evaluated in the sensitivity analyses to ensure 
relevance to countries with different personnel costs. Drug costs for erythromycin and doxycycline 
were calculated on the basis of accounting data from the Technical Support Services, Ministry of 
Health. The cost of azithromycin and upper and lower prices for the treatment regimens were 
collected from the International Drug Price Indicator Guide (102). The cost of testing and dispensing   41
were based on government salaries of health personnel, and registration and estimates of time used 
on procedures at the clinics. We used a salary range of +-50% to estimate the extent to which the 
expenditures for health personnel affected the results. The intention with this uncertainty range is to 
ensure relevance of the analysis in countries other than Botswana, and to cover the uncertainty 
regarding the time spent to perform the procedures. Costs from Botswana were obtained in 2006 
Botswana Pula (BWP) and converted to US dollars using average currency exchange rates for 2006 
(BWP1 = USD0.18). Details of the modeled costs are shown in Table 3. 
We assumed that following costs are covered in the antenatal program. 1. Capital costs: 
building costs, equipment and land and other capital-intensive items. 2. Overhead costs: resources 
that service different programmes, as expenses related to the building (e.g. power, rates), and costs 
associated with administration, transport, maintenance, cleaning etc. Intangible costs such as work 
time and leisure time forgone for care-givers and patients are not estimated. The attendees are 
routinely coming to the clinic, and the individuals’ costs (travel costs and expenditure on goods and 
services) will not be affected by the STI management strategy. 
 
SENSITIVITY ANALYSIS 
To test the robustness of model results, we undertook a range of sensitivity analyses. We first 
explored the consequences of parameter uncertainties in one-way sensitivity analyses, where one 
parameter at a time was varied up and down within the pre-specified uncertainty bounds while 
maintaining the others at their base-case values (Table 1-2). In these analyses, testing all new 
antenatal care attendees with a 50-85% sensitive POC test was compared to syndromic management 
in the same population, with azithromycin as treatment for C trachomatis infections in pregnancy.  
We also performed probabilistic sensitivity analyses using Monte Carlo simulation, allowing the 
effects of joint uncertainty across all the parameters of the model to be considered [62]. Universal   42
testing of antenatal care attendees, first with a 50% and then a 75% sensitive POC test, was compared 
to syndromic management, using azithromycin as the drug of choice. We adopted beta distributions 
for the probabilities to constrain the values between zero and one, and gamma distributions for the 
costs because of their skewness. The probabilities in the two strategies were linked to account for 
interdependencies.The model was run 10 000 times.  
 
Results 
Health outcome and costs 
Choice of antibiotics 
In an antenatal care population of 100 000 attendees with a 7.5% chlamydia prevalence, syndromic 
management and treatment with erythromycin would entail a total cost of $54 400 and result in 800 
cases of chlamydia cured ($66 per cured case) (Table 3). Replacing erythromycin with azithromycin 
would entail a total cost of $31 400 and result in 1 500 cases cured ($21 per cured case). In all 
scenarios, single-dose treatment with azithromycin implied lower cost and greater effectiveness than 
did treatment with erythromycin (Table 3). Therefore in the next sections we compare POC testing 
with the syndromic approach and universal versus age-based selective management using only the 
azithromycin treatment. 
 
POC tests versus the syndromic approach 
Testing all attendees with a 50% sensitive POC test priced at $0.85 would cost $106 800 and result in 
2 400 C trachomatis infections cured per 100 000 women ($87 per additional case cured) (Table 3). 
With increasing test sensitivity, the number of cases cured would increase further, while the cost of 
the programme would remain virtually unchanged, reducing the incremental cost per cured case.    43
 
Universal or selective management 
Restricting syndromic management or testing for chlamydia to teenage attendees would entail the 
lowest cost per case cured: $10 with the syndromic approach, $22 with a 50% sensitive POC test, and 
$15 with a 75% sensitive POC test (Table 3). Selective compared to universal syndromic 
management implies lower programme costs but results in fewer infections cured – as fewer women 
are included – and the same applies to the use of POC tests (Table 3). Reserving chlamydia treatment 
to teenagers would reduce the programme costs of syndromic management by 80%, but also reduce 
the number of cases cured by about 60%. Using a 75% sensitive POC test among teenagers, however, 
would be as effective as the syndromic management of chlamydia among all attendees, and the 
programme cost would be reduced from $31 400 to $22 425 (Table 3). 
 
Overtreatment and partner management 
In a population of 100 000 pregnant women, syndromic management and azithromycin treatment 
would result in 1 500 cured cases, although 29 900 individuals would be treated unnecessarily (Table 
4). The treatment costs would be $31 400, 90% of which represents treatment of uninfected 
individuals. Introducing the testing of all attendees with a 50% or 75% sensitive POC test would 
result in 2 400 or 3 500 cured infections and 1 790 or 1 870 individuals unnecessarily treated. 
Furthermore, drug costs wasted on uninfected individuals would be reduced by 95%. Selectively 
testing attendees less than 20 years of age with a 50% or 75%sensitive test would imply 980 or 1 460 
cases of chlamydia cured and 290 or 310 individuals unnecessarily treated, reducing drug wastage to 
1% of the current level.    44
With syndromic management, 140 of the estimated 6 000 infected partners would be 
successfully treated (Table 5). Using a 50% or 75% POC test would increase this number to 570 or 
850, which also would reduce reinfection rates. The majority of attendees diagnosed with syndromic 
approach are uninfected, and increasing partner attendance from the current 8.5% to 50% would 
result in 1 200 more cases cured per 100 000 attendees – while 11 700 additional uninfected partners 
would be unnecessarily treated. Increasing partner attendance to 50% when using 50% or 75% 
sensitive POC tests would result in 1 300 or 2 100 more cases cured, while 700 or 900 additional 
partners would be treated unnecessarily. 
  
Model uncertainty  
In the one-way sensitivity analyses, the cost of the POC test had its greatest impact on the 
incremental cost per case cured of introducing POC tests (Figure 2). High chlamydia prevalences 
result in the lowest incremental cost per additional case cured; decreasing from $91.80 in populations 
with 3% prevalence to $11.00 in populations with 31% prevalence (Table 6). The probability of a 
partner being notified and attend health care with the POC-test strategy was also an importanat 
factor; the incremental cost per additional case cured ranged from $69.90 with poor attendance to 
$18.10 with optimal performance. For the remaining model parameters, realistic changes in values 
made little difference to the results. 
As for the probabilistic sensitivity analyses, using POC tests was more effective and more 
costly than was the syndromic approach in practically all model iterations. The incremental number 
of infections cured with a 50% or 75% sensitive POC tests varied from -250 to 4 100 or from 500 to 
7 200 per 100 000 women screened. The additional cost ranged from $  58 700 to $94 700 or from 
$ 60 800 to $96 200. In Botswana, health authorities currently pay about $66 per cured infection with   45
C trachomatis. Adopting this willingness-to-pay threshold, replacing syndromic management with 
POC tests of all attendees had a 29% probability of being cost-effective with a 50% sensitive test and 
94% with a 75% sensitive test (Figure 3).  
 
Discussion 
The results of this study indicate that there may be substantial benefits in changing current diagnostic 
and treatment strategies for chlamydia in antenatal care in sub-Saharan Africa. The prevailing 
syndromic management of all attendees appears to be the least effective; it incurs high costs per case 
cured and entails considerable overtreatment.  
The study is limited by uncertainties in several of the model parameters. There is a paucity of 
high-quality studies providing data relevant for sub-Saharan Africa, and many probabilities are based 
partly on expert advice. For the POC-test strategy, the level of correct prescription, patient 
compliance and partner notification have a high degree of uncertainty, and were provided with broad 
uncertainty ranges. The sensitivity analyses show that partner notification with POC tests is 
important for the effectiveness of the strategy, also indicating the potential impact of strategies to 
improve partner notification. The cost of the POC test, which was the largest source of variation in 
the results, will be known by authorities who consider implementating a POC-test strategy.  
Large evidence gaps and conflicting evidence exist regarding chlamydia-related 
complications and their economic consequences.[89, 90] Because of this lack of knowledge, 
especially for developing countries, cured infections was used as the effect measure; thus important 
health benefits of case detection and treatment are not captured in this analysis. Short-term outcomes 
are not ideal for making policy recommendations, but as the existing management requires 
substantial resources, information about possibilities for more advantageous resource allocation   46
should be highly relevant to health policy makers. If successful chlamydia treatment reduces 
complications such as neonatal infections and post-partum infections, or reduces HIV transmission, 
[5, 6] it would strengthen the conclusions of this study.[52]  
To our knowledge, no studies in resource-poor settings have explored the costs and health 
consequences of chlamydia management strategies in pregnancy. One study has estimated the 
incremental cost-effectiveness of using POC tests for chlamydia and gonorrhoea among sex workers 
in Benin. Compared to syndromic management, such tests were cost-effective; averting HIV 
infections and decreasing inappropriate treatment.[26] Reviews of economic evaluations, mainly 
from developed countries, indicate that chlamydia screening is cost-effective, depending on 
prevalence; azithromycin is cost-effective; and partner notification is essential.[52, 62] The studies 
showed considerable variability with regard to probabilities used, complications and costing 
considered, and were hampered by methodological problems. The reviews point out the need for 
more data, particularly on the risk of complications. 
We used a static model to evaluate the chlamydia management of antenatal care attendees, a 
relatively small, non-core group within the total population. Static models assume constant infection 
prevalence, even when strategies result in fewer or more infections being cured. In contrast, dynamic 
models incorporate the impact of changes in strategy on infection prevalence. In recent years, the use 
of dynamic models has been advocated.[62, 23] However, chlamydia programmes targeting pregnant 
women are less likely to lower prevalence, and have been specifically mentioned as an example in 
which static models may be the preferred option.[54]
  
  Botswana was used as the case for this analysis, but the model should be applicable to other 
sub-Saharan countries. In the majority of countries in the region, 70% or more of pregnant women 
attend antenatal care at least once,[54] providing a convenient framework for diagnosis, treatment   47
and follow-up. Botswana is classified as “upper-middle income”, but the cost estimates will 
nevertheless be applicable to less wealthy settings with lower labour costs. The cost drivers in the 
model are POC tests and drugs purchased in international markets, and these prices will be relatively 
similar across countries. The sensitivity analysis indicates how higher or lower parameter values 
would change the results. To the extent that model data differ from those of other countries, the 
analysis can be revised on the basis of local data. 
Improving maternal and perinatal conditions and combating HIV/AIDS received substantial 
attention in the Millennium Declaration.[91, 92] It has been said that if countries are to have any 
chance of achieving their development goals, they need to re-evaluate existing strategies and replace 
less effective strategies with more effective ones.[93] Treatment of STIs is a strategy area that has 
already been prioritized in sub-Saharan Africa.[94] Chlamydia management in pregnancy is well 
within the scope of the development goals, and this study points to changes in diagnosis and 
treatment which may contribute to achieving these goals.  
First, single-dose treatment with azithromycin should be preferred, providing lower costs and 
higher efficacy than does the week-long erythromycin regimen. Azithromycin is safe in pregnancy, 
with fewer side effects and less interaction with other drugs.[42] Second, POC tests are necessary to 
improve effectiveness and reduce excessive overtreatment with the current management. In 
Botswana, the direct cost of introducing POC tests in antenatal care would increase the total health 
expenditure by 0.006%, an investment which may be more than offset by the reduced cost of the 
medical consequences of infection. Third, targeted partner notification is a good argument for 
introducing specific POC tests. Managing sexual partners of STI patients is essential to prevent 
reinfection, cure partners, break the chain of transmission and prevent complications;[12] In studies 
from Africa, partner notification has been associated with potential harm, including domestic   48
violence, and using an unspecific syndrome diagnosis as a basis for notifying partners is 
questionable.[12, 17] If POC tests are introduced, however, patient-delivered medication or 
information for partners should be considered.[66] Finally, the use of POC tests entails lowest 
incremental cost per case cured in populations with high prevalence. Adoption of age-restricted 
chlamydia treatment will entail lower programme costs and be more cost-effective than would the 
management of all pregnant women. Testing pregnant teenagers may be a feasible and reasonable 
way of introducing POC tests for chlamydia to antenatal care programmes in sub-Saharan Africa. 
Before recommending the routine use of POC tests in developing countries, carefully designed 




The results of this study indicate that sub-Saharan countries can substantially improve the 
management of chlamydia in antenatal care. Changes in diagnostic and treatment strategies may 
improve maternal and infant health as well as resource use. 
 
Key messages 
•  The use of single-dose azithromycin for the treatment of chlamydia in pregnancy was more 
effective and less costly than is the use of erythromycin. 
•  Moderately sensitive but highly specific POC tests may substantially improve case detection 
and treatment, and dramatically reduce the massive overtreatment that exists with syndromic 
approach.   49
•  The use of POC tests will entail lowest incremental cost per case cured in high-prevalence 
settings, and their effectiveness will increase with optimal partner notification. 
•  Testing all teenagers with a 75% sensitive POC test was equally effective and less costly than 
the current syndromic management strategy was. 
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Patient group  
 
Evidence of effectiveness 
 
 




Measure of effectiveness 
 






In the management of chlamydia infection among antenatal care attendees, 
what are the incremental costs and health benefits of  
a)  Replacing syndromic management with point-of-care tests? 
b)  Replacing erythromycin with azithromycin treatment 
c)  Replacing universal management with an age-based selective 
management strategy? 
 
Cost-effectiveness analysis performed within a static decision tree model 
 
Syndromic approach versus point-of-care tests. For each of these main 
strategies, we also compared universal and selective management strategies, 
and treatment with erythromycin or azithromycin. 
 
 Health care provider 
 
New antenatal care attendees 
 
Indirect evidence from a study on chlamydia among antenatal care attendees 




Costs of prescribing and providing treatment; cost of point-of-care test 
 
Successfully treated and cured infection 
 
The model captures events from a possible diagnosis of chlamydia at the first 
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Probabilities common to both strategies 
  Chlamydia trachomatis prevalence 
      Prevalence among all antenatal care attendees 
      Prevalence among attendees < 30 years 
      Prevalence among attendees < 20 years 
  Chlamydia trachomatis transmission rate 
  Infected male with symptomatic infection  
  Symptomatic male seeking care independently 
  Symptomatic male cured independently 
 
Variables in the syndromic approach strategy 
  Syndromic approach sensitivity 
  Syndromic approach specificity 
  Prescription of treatment to diagnosed attendee 
  Female compliant to erythromycin and drug effectiveness 
  Female compliant to azithromycin and drug effectiveness 
  Male partner notified and attended clinic 
  Prescription of treatment to attending partner 
  Male compliant to doxycycline and drug effectiveness 
   
Variables in the point-of-care strategy 
  Point–of-care test sensitivity 
  Point-of-care test specificity 
  Prescription of treatment to diagnosed attendee 
  Female compliant to erythromycin and drug effectiveness 
  Female compliant to azithromycin and drug effectiveness 
  Male partner notified and attends clinic 
  Prescription of treatment to attending partner 
































































Ref w1-w4, B 
Ref w10-w12, B 
Ref w12, w13, B 





Ref 14, A 
Ref 14, w14, w15, A, B 
Ref w14-w17 
Ref w11, w12, w18-w21 
Ref w22, w23, B 
Ref w15, w16, B 
 
 
Ref 9, 10, 17, w5, w24 
Ref 9, 10, 17, w24 
Ref 14, 22, 23, A, B 
Ref 14, w14, w15, A, B 
Ref w14-w17 
Ref w11, w12, w18-w21, w25, w26, B 
Ref 22, 23, w22, w23, w27, B 
Ref w15, w16, B 
 
A = Data from the original study among antenatal care attendees in Botswana; B = expert judgment. Further supporting evidence is 
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Table 2 Model costs (2006 US$) 
 








    Pharmacy technician 
    Lay worker 
    Dispensing (3 minutes x Cpharmacy technician) 
    Testing (5 minutes x Clay worker) 
Unit costs  
    Erythromycin  
    Azithromycin  
    Doxycycline  
































Ref w6, w7 




Ref w8, w9  
Ref w9  
Ref w8, w9  
Ref 7, 18 
Treatment (cost of drug + cost of dispensing)* 
    Erythromycin treatment 
    Azithromycin treatment 
    Doxycycline treatment 


















A = Data from the original study among antenatal care attendees in Botswana, C = Cost, POC = point-of-care 
*Modelled costs for the syndromic management strategy and the POC-test strategy 
† Modelled additional costs for the POC-test strategy 
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Table 3: Testing all women with point-of-care (POC) tests compared to syndromic approach (SA) – according to treatment regimen, universal- or age-based management 
and test sensitivity. Expected and incremental costs and effects per 1 000 attendees included in the programme, and total programme costs and effects in a population of 













Cost per  
cured case 
 (US$) 
Incremental cost  
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*Assuming that 19.5% of the attendees are less than 20 years of age and 74.0% are less than 30, and a C trachomatis prevalence of 15.8% among attendees less than 20 years of age and 9.3% among 
attendees less than 30 and 7.5% in the general population 
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Table 4: The number of female and male cases cured, the number of patients overtreated, total costs, drug costs* and costs of drug wastage†. Testing 
all women with a 50% or 75% sensitive point-of-care (POC) test compared to syndromic approach in a population of 100 000 antenatal care attendees‡.  
 








(US$)  % of drug 
costs 
% of total 
costs 
Syndromic approach 
Using POC tests (50% sensitivity) 
Using POC tests  (75% sensitivity) 
1 500 
2 400 
3 500  
29 910 
  1 790 
  1 870 




 5 300 








  1% 
  1% 
 
*Azithromycin treatment of pregnant women, doxycycline treatment of partners 
†Cost of drug wastage = monetary cost of treating uninfected antenatal care attendees or uninfected partners 
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Table 5: Expected number of antenatal care attendees and their partners diagnosed, treated* and cured. Testing all women with a 50% or 75% sensitive 
point-of-care test compared to syndromic approach in a population of 100 000 antenatal care attendees†.  
 
Partners notified and 
attended 




















































POC (50% test sensitivity) 





  1 390 





  1 290 













  250 
  750 
1130 




   350 
   350 
   210 
   700 
1 050 




   320 
  320 




CT+, C trachomatis infected; CT-, C trachomatis uninfected; SA, Syndromic approach; POC, Using point-of-care tests  
*Azithromycin treatment to pregnant women, doxycycline treatment to partners 
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Table 6 Sensitivity analysis: cost per additional case cured with a POC test compared to syndromic 
approach under different assumptions about model parameters*  
 
Variable  Parameter range  Cost (US$) per 
additional case 
cured with  
POC-test strategy† 








Probabilities common for both strategies 
  Chlamydia trachomatis prevalence 
  Chlamydia trachomatis transmission probability 
  Compliance to azithromycin and drug  effectiveness 
  Infected male with symptomatic infection  
  Symptomatic male seeking care independently 
  Symptomatic male cured independently 
Probabilities in the syndromic approach strategy 
  Syndromic approach sensitivity 
  Syndromic approach specificity 
  Prescription of treatment to test positive attendee 
  Male partner notified and attends clinic 
  Prescription of treatment to attending partner 
  Male compliant to doxycycline and drug effectiveness 
Probabilities in the point-of-care strategy 
  Point-of-care test sensitivity 
  Point-of-care test specificity 
  Prescription of treatment to test positive attendee 
  Male partner notified and attends clinic 
  Prescription of treatment to attending partner 
  Male compliant to doxycycline and drug effectiveness  
Costs ($/unit) 
  Cost of point-of-care test 
  Cost of treatment with azithromycin 
  Cost of treatment with doxycycline 
  Cost of testing 














































































































*Chlamydia management of all antenatal care attendees. First-line treatment regimens: Azithromycin to 
pregnant women, doxycycline to males. 
†Base-case results: The syndromic approach costs $21.00 per case cured; using POC tests costs $30.90 
per case cured, and the incremental cost of testing all women with a POC test is $38.10 per additional case 
cured.  
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Figure legends 
Figure 1 Key structure of the decision tree and its branches 
 
Figure 2 Tornado diagram summarizing one-way sensitivity analyses in which testing all women with 
a POC test is compared with syndromic management of chlamydia among 100 000 antenatal care 
attendees.  
 
Figure 3 Cost-effectiveness acceptability curves for testing all women with a POC test compared to 
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Appendix 1 
MEDLINE AND EMBASE SEARCHES FOR COST EVALUATIONS OF 
CHLAMYDIA SCREENING IN PREGNANCY 
 
MEDLINE IN PROCESS 27.6.06 
1.  Chlamydia trachomatis.mp.(89) 
2.  pregnancy.mp. (3825) 
3.  cost effectiveness.mp. (618) 
4.  economic evaluation.mp. (113) 
5.  1 and 2 and 3 (0) 
6.  1 and 2 and 4 (0)  
7.  mp=title, original title, abstract, name of substance word 
 
MEDLINE 27.6.06 
1.  Chlamydia trachomatis.mp. or exp Chlamydia trachomatis/ (9401) 
2.  pregnancy.mp. or exp Pregnancy/ (563782) 
3.  cost effectiveness.mp. or exp Cost-Benefit Analysis/ (44788) 
4.  1 and 2 and 3 (46) 
 
46 papers from 1987 to 2005 were identified and all abstracts read. 6 papers, of which four in English, 
presented cost evaluations of chlamydia testing among pregnant women. 
 
•  Rours et al. Use of pooled urine samples and automated DNA isolation to achieve 
improved sensitivity and cost-effectiveness of large-scale testing for Chlamydia 
trachomatis in pregnant women. Journal of clinical microbiology, Vol. 43, 2005. 
The authors compare costs per chlamydial infection detected with individual and 
pooled urine samples using different nucleic acid amplification test strategies. The 
urines are collected from pregnant women, but due to the temporary effectiveness 
measures the analysis is not specific for this patient group. 
•  Postma et al. [Screening for asymptomatic Chlamydia trachomatis infection in 
pregnancy; cost-effectiveness favourable at a minimum prevalence rate of 3% or more.] 
Ned Tijdschr Geneeskd, Vol 144, 2000. 
The paper is in Dutch. The authors present a pharmaco-economic model analysis of 
screening for chlamydia in pregnancy. The test used in the model was a ligase chain 
reaction test, infection was treated with erythromycin or amoxicillin, and the cost of 
major complications averted (neonatal pneumonia and conjunctivitis, pelvic 
inflammatory disease, extrauterine pregnancy, infertility, chronic pelvic pain) was 
calculated. As far as I can understand, the source for the outcomes averted is 
another cost-effectiveness analysis. 
•  Postma et al. Socio-economic aspects of extended STD screening in pregnancy. AIDS 
Care, Vol 12, 2000. 
•  Hueston and Lenhart. A decision analysis to guide antibiotic selection for Chlamydia 
infection during pregnancy. Archives of family medicine, Vol. 6, 1997. 
A decision analysis model to determine the cost of treatment and treatment failure 
rates of different drug treatment strategies. Treatment with amoxicillin, followed by 
azitromycin for non-responders was the most cost-effective strategy.  The study 
population was pregnant women, but due to the temporary effectiveness measures 
the analysis is not specific for pregnancy. 
•  Ottesen et al. [Chlamydia trachomatis in pregnant women in the country of Vestjaelland. 
Prevalence, prevention of perinatal transmission and cost-effectiveness of screening.] 
Ugeskrift for Laeger, Vol 158, 1996.   60
The paper is in Danish. This is a paper on prevalence of chlamydia among pregnant 
women in Vestjaelland. Of 339 women, 10 had chlamydia. All were treated with 
erythromycin, and among the 7 children who were tested, none had chlamydia. The 
authors provide a simple cost calculation of chlamydia testing in pregnancy, but not 
a formal cost evaluation. 
•  Nettleman and Bell. Cost-effectiveness of prenatal testing for Chlamydia trachomatis. 
Am J Obstet Gynecol, Vol 164, 1991. 
Nettleman and Bell analyse culture and direct antigen testing of pregnant women 
assuming different prevalences of infection. Probabilities of major outcomes averted 
were derived from published literature (1979-87). Available abstracts of these 
papers were collected. The authors conclude that screening all pregnant women is 
not cost-effective, but the excess cost was modest when direct antigen tests were 
used. 
Probability conjunctivitis 0.25 
Probability pneumonia 0.15, of which 75% receive outpatient therapy and 25% are 
hospitalized 
Probability post-partum endometritis/salpingitis 0.1, of whom 0.07 result in ectopic 
pregnancy 
Probability partner infected 1.0 
Probability epididymitis 0.04 
 
EMBASE (1980 to 2006 week 30) 2.8.06 
1.   Chlamydia trachomatis.mp. or exp Chlamydia Trachomatis/ (9365) 
2.  exp "COST OF REPRODUCTION"/ or exp "HOSPITAL COST"/ or exp "COST  
EFFECTIVENESS ANALYSIS"/ or exp "COST UTILITY ANALYSIS"/ or exp "HOSPITAL 
RUNNING COST"/ or exp "DRUG COST"/ or exp "COST BENEFIT ANALYSIS"/ or exp 
"COST MINIMIZATION ANALYSIS"/ or exp "COST"/ or cost.mp. or exp "HEALTH CARE 
COST"/ (196953) 
3.  exp PREGNANCY/ or pregnancy.mp. (211574) 
4.  1 and 2 and 3 (96) 
 
Among the 96 identified papers, titles and relevant abstracts were read. The search yielded no papers not 
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Appendix 2 
LITERATURE SEARCHES FOR COST EVALUATIONS OF CHLAMYDIA 
SCREENING IN DEVELOPING COUNTRIES 
 
MEDLINE IN PROCESS 7.8.06 
1.  Chlamydia trachomatis.mp. [mp=original title, abstract, name of substance word] (103) 
2.  Cost effectiveness.mp. [mp=original title, abstract, name of substance word] (596) 
3.  Cost.mp. [mp=title, original title, abstract, name of substance word] (4591) 
4.  1 and 2 (3) None from developing countries 
5.  1 and 3 (3) None from developing countries 
 
MEDLINE 1 (1966-July week 4 2006) 
1.  exp Chlamydia trachomatis/ (7905) 
2.  exp "Costs and Cost Analysis"/ (126280) 
3.  exp Developing Countries/ (47278) 
4.  exp AFRICA/ (116999) 
5.  combine 1 and 2 (138) 
6.  combine 3 and 5 (0) 
7.  combine 4 and 5 (1) 
 
Mayaud P. Grosskurth H. Changalucha J. Todd J. West B. Gabone R. Senkoro K. Rusizoka M. Laga M. 
Hayes R. et al. Risk assessment and other screening options for gonorrhoea and chlamydial infections in 
women attending rural Tanzanian antenatal clinics. [Journal Article. Multicenter Study] Bulletin of the 
World Health Organization. 73(5):621-30, 1995. 
 
MEDLINE 2 (1966-July week 4 2006) 
1.  Chlamydia trachomatis.mp. or *Chlamydia trachomatis (9495) 
2.  cost.mp. or *"Costs and Cost Analysis"/ (182891) 
3.  *Africa, Western/ or *Africa, Northern/ or *South Africa/ or *Africa, Eastern/ or africa.mp. or 
*Africa, Central/ or *"Africa South of the Sahara"/ or *Africa/ (57992) 
4.  developing countries.mp. or *Developing Countries/ (55890) 
5.  1 and 2 and 3 (7) None were economic analyses 
6.  1 and 2 and 4 (12)  
 
EMBASE (1980-2004 week 25) 
 
1.  exp Chlamydia Trachomatis/ (7546) 
2.  exp "COST OF REPRODUCTION"/ or exp "HOSPITAL COST"/ or exp "COST 
EFFECTIVENESS ANALYSIS"/ or exp "COST UTILITY ANALYSIS"/ or exp "ENERGY 
COST"/ or exp "HOSPITAL RUNNING COST"/ or exp "COST CONTROL"/ or exp "DRUG 
COST"/ or exp "COST BENEFIT ANALYSIS"/ or exp "COST MINIMIZATION ANALYSIS"/ 
or exp "COST"/ or exp "HEALTH CARE COST"/ or exp "COST OF ILLNESS"/ (122117)   
3.  exp Developing Country/ (13917) 
4.  combine 1 and 2 (232) 
5.  combine 3 and 4 (5) 
 
•  Damasus-Awatai G. Freeman-Wang T. Human papilloma virus and cervical screening. [Journal: 
Review] Current Opinion in Obstetrics & Gynecology. Vol. 15(6)(pp 473-477), 2003 
•  Chen MY. Donovan B. Screening for genital Chlamydia trachomatis infection: Are men the 
forgotten reservoir?. [Journal: Editorial] . Vol. (124-125)(pp 124-125).   62
•  Frick KD. Mecaskey JW. Resource allocation to prevent trachomatous low vision among older 
individuals in rural areas of less developed countries. [Journal: Review] Documenta 
Ophthalmologica. Vol. 105(1)(pp 1-21), 2002 
•  Frick KD. Colchero MA. Cost-effectiveness of alternative strategies to prevent trachomatous 
blindness. [Journal: Review] Expert Review of Pharmacoeconomics & Outcomes Research. Vol. 
2(3)(pp 219-228), 2002 
•  Van der Veen F. Fransen L. Drugs for STD management in developing countries: Choice, 
procurement, cost, and financing. [Journal: Article] Sexually Transmitted Infections. Vol. 
74(SUPPL. 1)(pp S166-S174), 1998 
 
EMBASE (1980-2004 week 25) 
 
1.  exp Chlamydia Trachomatis/ (7546) 
2.  exp "COST OF REPRODUCTION"/ or exp "HOSPITAL COST"/ or exp "COST 
EFFECTIVENESS ANALYSIS"/ or exp "COST UTILITY ANALYSIS"/ or exp 
"ENERGY COST"/ or exp "HOSPITAL RUNNING COST"/ or exp "COST 
CONTROL"/ or exp "DRUG COST"/ or exp "COST BENEFIT ANALYSIS"/ or exp 
"COST MINIMIZATION ANALYSIS"/ or exp "COST"/ or exp "HEALTH CARE 
COST"/ or exp "COST OF ILLNESS"/ (122117)   
3.  exp AFRICA/ (42518) 
4.  combine 1 and 2 (232) 
5.  combine 3 and 4 (4) 
 
•  Pepin J. Mabey D. Sexually transmitted infections in Africa: Single dose treatment is now 
affordable. [Journal: Editorial] Sexually Transmitted Infections. Vol. 79(6)(pp 432-434), 2003. 
•  MacLachlan EW. Baganizi E. Bougoudogo F. Castle S. Mint-Youbba Z. Gorbach P. Parker K. 
Ryan CA. The feasibility of integrated STI prevalence and behaviour surveys in developing 
countries. [Journal: Article] Sexually Transmitted Infections. Vol. 78(3)(pp 187-189), 2002 
•  Mukenge-Tshibaka L. Alary M. Lowndes CM. Van Dyck E. Guedou A. Geraldo N. Anagonou S. 
Lafia E. Joly JR. Syndromic versus laboratory-based diagnosis of cervical infections among 
female sex workers in Benin: Implications of nonattendance for return visits. [Journal: Article] 
Sexually Transmitted Diseases. Vol. 29(6)(pp 324-330), 2002 
•  El-Shourbagy M. Abd-El-Maeboud K. Diab KM. El-Ghannam A. Nabegh L. Ammar S. Genital 
Chlamydia trachomatis infection in Egyptian women: Incidence among different clinical risk 
groups. [Journal: Article] Journal of Obstetrics & Gynaecology Research. Vol. 22(5)(pp 467-472), 
1996. 
 
EMBASE 2.8.06 (1980 to 2006 week 30) 
        1. Chlamydia trachomatis.mp. or exp Chlamydia Trachomatis/ (9365) 
2.  exp "COST OF REPRODUCTION"/ or exp "HOSPITAL COST"/ or exp "COST 
EFFECTIVENESS ANALYSIS"/ or exp "COST UTILITY ANALYSIS"/ or exp "HOSPITAL 
RUNNING COST"/ or exp "DRUG COST"/ or exp "COST BENEFIT ANALYSIS"/ or exp 
"COST MINIMIZATION ANALYSIS"/ or exp "COST"/ or cost.mp. or exp "HEALTH CARE 
COST"/ (196953) 
3.  developing countries.mp. or exp Developing Country/ (23427) 
4.  exp AFRICA/ or africa.mp. (59484) 
5.  1 and 2 and 3 (20) All abstracts read, none were relevant. 
6.  1 and 2 and 4 (14) All abstracts read, none were relevant. 
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Appendix 3 
IMPROVING PUBLIC HEALTH CONTROL OF STIS IN BOTSWANA: 
METHODS OF THE EPIDEMIOLOGICAL STUDY 
 
Participating in this study were 703 pregnant women who visited the 13 main facilities 
providing antenatal care in Gaborone, Botswana: 12 primary health clinics and one 
outpatient department. A proportionate sample of attendees was recruited from each 
location. This proportion corresponded to the percentage of all antenatal care attendees 
in Gaborone who visited that facility during the previous year. Facilities were visited 
one-by-one by a medical doctor between October 2000 and February 2001. In the 
majority of clinics, all attendees were included in the study. In the busiest clinics, only a 
sample of the attendees was included; the selection of attendees in these clinics was 
incidental. Approximately one out of every four antenatal care attendees in Gaborone 
was included in the study during the period of data collection. All participants gave 
written, informed consent. The only exclusion criterion was the use of antibiotics during 
the previous two weeks.  
  A structured interview and information from the patient-held antenatal record 
were used to obtain data on sociodemographic and behavioural factors, current RTI 
symptoms, and diagnosis and prescribed treatment for such conditions earlier in the 
pregnancy. All patients underwent a genital examination; appropriate specimens were 
collected; and abnormal signs from external and internal genitalia were recorded in detail. 
Symptoms and signs of a reproductive tract infection were classified into defined 
syndromes following the national STI guidelines and were treated accordingly. Women   64
diagnosed with the vaginal discharge syndrome were treated for chlamydia, gonorrhoea, 
trichomoniasis, bacterial vaginosis and vulvovaginal candidiasis in accordance with the 
treatment guidelines. 
  Urine was checked on site with a dipstick; all other specimens were analysed at 
the National Health Laboratory in Gaborone. Cervical swabs were obtained for ligase 
chain reaction (LCR) amplification technology for detection of C trachomatis and N 
gonorrhoeae. The swabs were placed in LCx® transport media, transported to the 
laboratory the same day, and stored at -20
o C prior to batch processing.  The LCx® 
Assays (Abbott Laboratories, IL) were performed according to the manufacturer’s 
instructions. A case of C trachomatis infection was defined as an individual with a 
positive LCR analysis, used as the reference standard when evaluating the syndromic 
approach.    
  A high vaginal swab for identification of Trichomonas vaginalis was placed in 
Stuart transport media. Before culturing, a wet-mount was made and examined for the 
presence of motile trichomonads by light microscopy, 100 x magnification. The swab 
was then agitated into a bottle of Diamond’s modified medium. The bottles were 
incubated with indicators in Oxoid gaspack jars (3.4 litres, with anaerobic system BR 
038B). Wet-mounts from the cultures were examined once a day for five days by light 
microscopy.  
  Gram-stained vaginal smears were scored for bacterial vaginosis according to 
Nugent’s criteria [20]. Culture of Candida species was initiated by direct inoculation of a 
high vaginal swab on Saboraud plates on site, and Gram-stained smears and wet-mounts 
from high vaginal swabs were examined for budding yeast cells and pseudohyphae. A   65
cervical smear was gram-stained to count polymorphonuclear leukocytes per high power 
field (PMN/HPF). 
  Data were analysed using the statistical package SPSS, Version 11. To evaluate 
the clinical diagnosis of chlamydia, univariate logistic regression analyses were used to 
assess the association between genital symptoms and signs and the laboratory-verified 
diagnosis. Socio-demographic risk factors and genital symptoms and signs which in 
univariate analysis were associated at a 0.2 level (p-value of odds ratios (OR)), were 
included in multivariate logistic regression analysis. The validities of the vaginal 
discharge algorithm were assessed by measuring sensitivity, specificity, positive and 
negative likelihood ratios (LR+ and LR-) and positive and negative predictive values 
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Appendix 4 
MEDLINE SEARCHES FOR THE VARIABLES IN THE DECISION TREE 
 
 
Nurses’ adherence to prescription guidelines 
 
Medline in process 20.6.06 
1.  Chlamydia trachomatis 
2.  Prescription 
3.  1+2 
No papers found 
 
Medline 20.6.06 
        1.    Chlamydia trachomatis.mp. or exp Chlamydia trachomatis/ 9381 
        2.    prescription.mp. or exp Prescriptions, Drug/ 34 299 
        3.    1+2 
7 papers identified. Titles and abstracts read, none were studies or reviews on drug prescription. 
 
 
Compliance to prescribed treatment 
 
Medline in process 13.6.06 
1.  Sexually transmitted diseases 
2.  Compliance 
3.  1+2 
No papers found 
 
Medline 13.6.06 
1.  Sexually transmitted diseases.mp. or exp Sexually Transmitted Diseases/ 
2.    Erythromycin.mp. or Erythromycin/ 
3.    Compliance.mp. or *Compliance/ or *Patient Compliance/ 
4.    1+2+3 





Medline in process 10.5.06 
1.   Chlamydia trachomatis 
2.   Sexual partners 
3.   1 + 2 
One paper identified, not on the topic of concurrent infections. 
 
Medline 10.5.06 
1.   Chlamydia trachomatis 
2.   Sexual partners 
3.   1 + 2 
132 papers published from 2001-2006 identified. Titles and abstracts read and if relevant, full text 
obtained. 
 
1.  Quinn et al. report a study of 494 couples attending an STI clinic in the USA, 53 couples were 
concordantly infected with chlamydia, while in 48 couples one of the partners were infected. 78   67
females had chlamydia, of whom 53 (68%) of the male partners were infected (95% CI 57-77% 
MR). 76 males had chlamydia, of whom 53 (70% (95% CI 59-79% MR).) of the female partners 
were infected. Approximately 90% were steady partners, and the participants reported median 6 
intercourses the last 30 days. The number of episodes of intercourse did not correlate with 
infection status.  
2.  Markos reports a concordance of chlamydia trachomatis between sexual partners of 0.75. The 
study was conducted in an STI clinic, UK. 97 males and 93 females were chlamydia positive, half 
of their partners were tested. 
3.  Manavi et al report that 404 women in their UK study were infected with chlamydia based on 
PCR. The women, who had sought care in an STI clinic, reported 632 contacts. 155 (23%) males 
attended the clinic and 147 were tested. Of these men, 64 (44%) had a chlamydia infection.  
4.  Mak et al report from their Australian study that 126 index cases had gonorrhea and 87 had 
chlamydia. 53% and 52% of the sexual contacts of the respective index cases who came to the 
health facility had a concordant infection.  
5.  In a Japanese study (Okazaki et al), the infection rate of chlamydia in 149 sexual partners with 
pregnant wives with c trachomatis diagnosed by antibody or antigen test. Antibody-positive rate 
was 60% (90/149 cases) and antigen positive rates was 7% (11/149). Noteworthy, the detected 
concordance seems to be dependent of the diagnostic test used. 
 
 
Partner notification with syndromic approach  
 
Medline 4.5.06 
        1.   *Sexually Transmitted Diseases/      8943 
        2.   partner notification.mp. or exp Contact Tracing/  1926 
        3. 1 and 2              232 
        4. exp Africa, Western/ or exp Africa, Northern/           120 871 
            or South Africa/ or exp Africa, Eastern/ or africa.mp. or exp Africa, Central/ or  
            exp "Africa South of the Sahara"/ or exp Africa/ or exp Africa, Southern/ 
        5. 3 and 4                36 
Abstracts on relevant papers obtained and read 
 
1.  A Cochrane review on partner referral strategies report the following: Only two studies were 
conducted in developing countries, one unpublished and one unrepresentative [Mathews et al. 
2001]. All studies identified had some risk of bias, and none had pregnant women as index 
patients. In the unpublished study from South Africa reports with patient referral and contact cards 
that the STI clients reported mean 1.04 partners, while 0.18 partners were reported treated by the 
index patient. The other trial among patients with NGU resulted in 0.18 partners receiving 
treatment with the patient referral strategy.  
2.  A trial among STI clients from Uganda compared the efficacy of patient delivered partner 
medication with patient referral [Nuwaha et al. 2001]. STIs were diagnosed and managed 
according to the syndromic approach, and all patients were given IEC regarding the importance of 
partner treatment (5-10 min). Index patients were either given contact slips to pass to their sexual 
partners or medication to take to the partners. Index patients were asked to return to the clinic 
within 2 weeks and asked if they referred their partners/if the partner took the medication. In the 
medication group, 93 female patients reported 103 partners, and 86 (83%) partners were reported 
to have taken the medication. In the patient referral group, 94 female patients reported 104 
partners, and 23 (22%) of these were referred. These results are from an optimal study setting, and 
may represent the highest partner treatment rates achievable. 
3.  Paxton et al report from Uganda that 4% of symptomatic women notified their partners (how many 
partners who sought care after being notified is not known) [Paxton et al. 1998].  
4.  A study in South Africa evaluated the effect of a video based health education strategy to improve 
partner notification [Mathews et al.]. The rate of contact cards returned per index patient in the 
control phase was 0.2, and increased to 0.27 in the intervention phase. 
   68
 
Partner notification with diagnostic testing (in pregnancy) 
 
Medline 4.5.06 
        1. *Chlamydia trachomatis/ or *Chlamydia/      5 913 
        2. contact tracing.mp. or *Contact Tracing/ or*Sexual Partners/   3 477 
            or partner treatment.mp 
        3. Pregnancy/                    520 794 
        4. 1 and 2                   101 
        5. 3 and 4                   17 
Abstracts on relevant papers obtained and read 
 
1.  According to the Cochrane review on partner referral strategies, contract referral is more effective 
than patient referral. In a study by Cleveland et al, partners attending the clinic increased from 
0.31 to 0.62 per patient [Mathews et al. 2001]. 
2.  In a study from Amsterdam, 60% of all male contacts of female STI clients were referred; 81.5% 
of the steady partners. The contact tracing strategy included a thorough interview and follow up by 
a public health nurse [van de Laar et al. 1997].  
3.  In a study from general practice in the UK, 65% of participants receiving practice nurse led partner 
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Appendix 5 
LITERATURE REVIEWS: COMPLICATIONS OF CHLAMYDIA 
We performed a (semi-) systematic literature review to get an overview of studies and 
other published material (and identify explicit knowledge on) the complications of C 
trachomatis-infection in pregnant and non-pregnant women in developing countries. The 
prevalence of C trachomatis and its complications in developing countries is likely to 
have other epidemiological characteristics than in the developed world. Unfortunately, 
due to lack of research and partly also lack of knowledge, opportune diagnosis and little 
technological resources, information from developing countries is virtually non-existing. 
We therefore also conducted literature searches on pregnancy-related complications 
among women in without restricting the search to developing countries. 
The searches were performed in the largest biomedical literature bases: 
MEDLINE, EMBASE and The Cochrane Library. To limit the search, we selected the 
following main key words: Chlamydia trachomatis and complications. We also did a 
search for pregnancy related complications: Chlamydia trachomatis and premature 
labour or premature infant or pregnancy complications. We subsequently limited our 
searches by including developing countries as a key word. We also tried to vary the key 
words to avoid missing relevant literature (for example changing “developing countries” 
to “Africa” or “third world”). Abstracts of papers and reports identified as relevant in the 
searches were read, and we got access to and read papers and reports which we found 
having relevance to the described aim of the literature review. We also identified, 
collected and read papers, reports and books referred to in the originally identified   70
material (the snowball strategy). The content of the material collected is described in 
detail below. 
 
All complications - developing countries 
 
 







1.  exp Chlamydia Trachomatis, Subject Heading (7540) 
2.  exp NEUROLOGICAL COMPLICATION/ or exp UTERINE COMPLICATION/ 
or exp INFECTIOUS COMPLICATION/ or exp PEROPERATIVE 
COMPLICATION/ or exp POSTTRAUMATIC COMPLICATION/ or 
complications.mp. or exp INFECTION COMPLICATION/ or exp 
POSTOPERATIVE COMPLICATION/ or exp COMPLICATION/ or exp 
LABOR COMPLICATION/ or exp ANESTHESIA COMPLICATION/ or exp 
PREGNANCY COMPLICATION/ or exp LUNG COMPLICATION/ (359846) 
3.  developing countries.mp. or exp Developing Country/ (18749) 
4.  combine 1 and 2 and 3 (8) 
5.  of 8 abstracts read, we found two possibly relevant papers: 
 
Update on the impact of Chlamydia trachomatis infection on male fertility. Journal: Review. 
Gonzales et al., Andrologica. Vol. 36(1)(pp1-23), 2004 
This review has a focus on male infertility in the developed world. The authors describe several 
complications of C trachomatis also in women, with references (from the developed world): 
•  The incidence of the infection in women having spontaneous abortions is about 21% 
compared with 9% in the control group. When at least one partner of the couple is 
infected, the spontaneous abortion rate risis to 59% (Virgil et al, 2002) 
•  In a recent meta-analysis including 23 studies with a total of 2729 patients, the 
discriminative capacity of chlamydial antibody titres in the diagnosis of any tubal 
pathology was comparable with that of HSG in the diagnosis of tubal occlusion (Mol 
et al, 1997) 
•  Chlamydial infections are also acquired by the newborn during delivery and account 
for 25-50% of conjunctivitis and 10-20% of pneumonia in these children (Fenton, 
2000) 
•  Routine screening of asymptomatic women for chlamydial infection and treating 
those identified as infected has been shown to reduce the incidence of PID (Scholes 
et al, 1996) 
•  There is some evidence that C trachomatis may contribute to pregnancy 
complications other than ectopic pregnancy, such as premature rupture of 
membranes, premature birth and low birth weight or stillbirth (Gravett et al, 1986)   71
 
Genital infections and reproductive health: Infertility and morbidity of mother and child in 
developing countries. Bergstrom, Scandinavian Journal of Infectious Diseases, 1990. 
Abstract: Gonorrhea and chlamydia infection give few maternal problems during pregnancy but 
may be more important as a cause of puerperal endometritis-myometritis, which constitutes one 
of the leading causes of maternal death in many developing countries. The fetal/neonatal infant 





th of June 2004) 
 
1.  MeSH Chlamydia trachomatis (233) 
2.  MeSH Female genital diseases and pregnancy complications (9992) 
3.  Developing countries (309) 
4.  1 and 2 and 3 (0) 
5.  1 and 3 (1) 
 
Diagnosis of ophthalmia neonatorum, Winceslaus J, Goh BT, Dunlop EM, Mantell J, 
Woodland RM, Forsey T, Treharne JD, British Medical Journal Clinical Research Ed. 1987. 
Ninety consecutively seen babies with eye discharge in the first three weeks of life were 
examined. Four babies had "sticky eyes" with no evidence of ophthalmia and had uniformly 
negative cultures and test results for antichlamydial antibody; these babies were excluded. Of the 
86 babies with ophthalmia neonatorum, Neisseria gonorrhoeae was isolated from eight, 
Chlamydia trachomatis from 44, other bacteria alone from 20, and 14 had negative cultures. 
Three babies with negative cultures had longstanding conjunctivitis and had been treated with 
chloramphenicol eye ointment; all had antichlamydial IgM antibodies, indicating that the 
conjunctivitis was chlamydial. Hence the total number of babies whose conjunctivitis was 
chlamydial was 47. The result of the Gram stained conjunctival smear correlated well with that of 
culture and final assessment by the microimmunofluorescence test, enabling an immediate 
presumptive diagnosis to be made of gonococcal, chlamydial, or bacterial conjunctivitis. Prompt 
and effective treatment of babies was started. Explanation to the mother and contact tracing were 




th week of May 2004) 
 
1.  exp Chlamydia trachomatis/ (6997) 
2.  exp Developing Countries/ (42300) 
3.  exp PREGNANCY COMPLICATIONS, INFECTIOUS/ or exp PREGNANCY 
COMPLICATIONS/ or exp PREGNANCY COMPLICATIONS, NEOPLASTIC/ 
or exp POSTOPERATIVE COMPLICATIONS/ or exp PREGNANCY 
COMPLICATIONS, PARASITIC/ or exp LABOR COMPLICATIONS/ or exp 
PREGNANCY COMPLICATIONS, CARDIOVASCULAR/ or exp 
INTRAOPERATIVE COMPLICATIONS/ or exp PREGNANCY 
COMPLICATIONS, HEMATOLOGIC/ (481085) 
4.  1 and 2 and 3 (1)  
   72
Frequency of Chlamydia trachomatis in pregnant women. [Journal Article] Kirmani N. Hafiz 




Preterm birth and low birth weight - developing countries 
 
MEDLINE (1966-4
th week of May 2004) 
 
1.  exp Chlamydia trachomatis/ (6997) 
2.  exp Labor, Premature/ or exp Pregnancy Outcome/ or exp Infant, Premature/ 
(49133) 
3.  1 and 2 (90) 
4.  exp AFRICA/ (102054) 
5.  exp Developing Countries/ (42300) 
6.  3 and 5 (0) 
7.  3 and 4 (2) 
 
1. el-Shourbagy M. Abd-el-Maeboud K. Diab KM. el-Ghannam A. Nabegh L. Ammar S. Genital 
Chlamydia trachomatis infection in Egyptian women: incidence among different clinical risk groups. 
[Journal Article] Journal of Obstetrics & Gynaecology Research. 22(5):467-72, 1996 Oct.  
UI: 8987330 
 
2. Donders GG. Desmyter J. De Wet DH. Van Assche FA. The association of gonorrhoea and syphilis with 
premature birth and low birthweight. [Journal Article] Genitourinary Medicine. 69(2):98-101, 1993 Apr. 
 
 
Preterm birth and low birth weight - all countries 
 
MEDLINE (1966-4
th week of May 2004) 
 
8.  exp Chlamydia trachomatis/ (6997) 
9.  exp Labor, Premature/ or exp Pregnancy Outcome/ or exp Infant, Premature/ 
(49133) 
10. 1 and 2 (90)  
11. Limited to 11 full texts and 3 abstracts 
 
Of 90 papers identified, we decided to limit our further reading to papers published in 1997 or 
later. This was due to the fact that we had read Andrews et al: The preterm prediction study, 
published in 2000, who summarizes findings from earlier years as “non conclusive” (see 
summary of the paper). 
 
Of the 31 titles, we chose to read 11 full texts and three abstracts which were thought to be 
relevant. 
 
Full text papers 
 
1.  Effect of treatment for Chlamydia trachomatis during pregnancy. Rastogi et al, 
International Journal of Gynecology and Obstetrics 2002. 15 patients were chlamydia   73
positive and successfully treated for CT (group 1). 26 patients were CT positive and not 
treated (group 2). 127 patients were CT negative (group 3). Results: The main duration of 
premature deliveries were lower in group 2 compared with group 1 (33.1 vs 35.5 weeks). 
Stillbirths were significantly higher in group 2 than group 3 (11.5% vs 4.7%). 
Weaknesses: few cases and no multiple regression to adjust for confounders. Conclusion: 
Can not be used in our model. 
 
2.  Immunological aspects of genital chlamydia infections. Witkin, Best Practice & 
Clinical Obstetrics and Gynaecology 2002. Not relevant. 
 
3.  Influence of infection with Chlamdyia trachomatis on pregnancy outcome, infant 
health and life-long sequelae in infected offspring. Mårdh, Best Practice & Clinical 
Obstetrics and Gynaecology 2002. Mårdh describes all possible complications with 
thorough literature references, although the quality of these studies is unknown there are 
no estimates on the prevalence of these complications.  
-Early spontaneous abortion (Indian study; women more likely to have chlamydial 
 antigen detected in endometrial curettage samples than controls) 
-Late spontaneous abortion, recurrent spontaneous abortion 
-Studies have postulated an association between C trachomatis infection and both PROM 
 and premature birth. Gravett et al (1986) found in a case-control study that chlamydia in   
 mothers was associated with premature birth at <37 weeks (OR 4.4). A correlation has 
 been demonstrated between adverse pregnancy outcome and anitchlamlydial serum IgM  
 (but not IgG) antibodies, on the one hand, and adverse pregnancy ooutcome on the other  
 (13 of 67 IgM+ and 8 of 99 IgM-). The authors assumed that women with a recent and  
 probably acute ongoing chlamydial infection were at risk of preterm delivery.  
 Statistical correlation between genital chlamydial infection in mothers has generally 
 been performed late in pregnancy and often not adjusted for other known aetiological 
 factors for prematurity, including infectious agents other than C trachomatis. 
 
 
4.  The role of infection in preterm labour and delivery. Romero et al, Paediatric and 
Perinatal Epidemiology 2001. The paper gives thorough theoretical background on the 
issue, with references. Re chlamydia: The role of C trachomatis as an intrauterine 
pathogen has not been clearly elucidated. This microorganism is an important course of 
cervicitis and has been recently isolated from amniotic fluid (ref). A case of congenital 
pneumonia caused by C trachomatis suggests that this micro-organism may be capable of 
causing ascending intra-amniotic infection (ref). The uncertainty about the role of C 
trachomatis in the aetiology of microbial invasion and intrauterine infection may be 
related to difficulties in isolating the micro-organisms from amniotic fluid with standard 
culture techniques. The use of PCR to detect specific sequences for this micro-organism 
should help resolve this question. 
 
5.  Chlamydia trachomatis infection and the risk of perinatal mortality in Hungary. 
Nyari et al, Journal of Perinatal Medicine 2001. Epidemiological study of C trachomatis 
infection among pregnant women admitted to the hospital before labor: 6156 women, 
prevalence of infection 5.9%. Bivariate analysis showed a slight, but significant 
difference between the rate of premature uterine activity that occurred in the infected 
group than in the non-infected (8.1 vs. 5.3). PROM occurred in 21% of the infected and 
19.9 on the non-infected. Perinatal mortality occurred in 148 (2.4%) of all pregnancies. 
Multiple regression showed a higher risk of perinatal mortality among C trachomatis-
infected women (OR 1.9), low birth weight (OR 1.7), no pervious delivery (OR 1.9) and   74
high rate of unemployment (1.5), adjusted for age, demographic and social status, C 
trachomatis infection, previous pregnancy, previous delivery, low birth weight, PROM, 
and intrauterine distress or growth retardation –but not adjusted for any other microbial 
infections. 
 
6.  Chlamydia trachomatis seropositivity is associated both with stillbirth and early 
preterm delivery. Gencay et al, APMIS 2000. A case “control” study which finds and 
association between C trachomatis antibodies and both stillbirth and preterm delivery, 
however not controlling for any confounding factors. The authors conclude that C 
trachomatis is an important agent associated with stillbirth and preterm delivery, making 
screening for genital chlamydial infection highly relevant especially when viewing the 
therapeutic possibilities. In mothers with stillbirth, the observed high IgG seropositivity 
rate indicates a past or persistent infection, whereas in extreme preterm delivery cases, 
the involvement of acute infection was suggested 
IgG   IgM   Tot 
72 consecutive stillbirths      20(28%)  1(1%)    24(33) 
48 preterm deliveries between week 23 and 29    6(13%)  4(8%)      9(19) 
96 consecutive liveborn deliveries    10(10%)  0 -    10(10) 
 
7.  The preterm prediction study: Association of second-trimester genitourinary 
chlamydia infection with subsequent spontaneous preterm birth. Andrews et al, Am J 
Obst Gyn 2000. 
This is a retrospective case-control study within The Preterm Prediction Study where 
2929 pregnant women were evaluated longitudinally to determine risk factors for 
spontaneous preterm birth. This study consist of 117 case patients with a spontaneous 
preterm birth at <37 weeks with corresponding matched control subjects.  
After adjustment for risk factors for spontaneous preterm birth, women with C 
trachomatis infection at 24 weeks gestation were 2 times as likely as uninfected women 
to have a spontaneous preterm birth at <37 weeks gestation and 3 times as likely to have a 
spontaneous preterm birth at <35 weeks gestation. Whether universal screening and 
treatment for C trachomatis infection with a sensitive NAAT method for detection would 
significantly reduce spontaneous preterm delivery remains an unanswered question. 
 
8.  A murine model for the study of Chlamydia trachomatis genital infections during 
pregnancy. Pal et al, Infection and immunity, May 1999. In our murine model, we have 
shown that C trachomatis inoculated intra-vaginally on day 5 of gestation in mice infects 
the endometrium and the membranes of the yolk sac, resulting in early termination of 
pregnancy. This is not surprising since chlamydial endometritis commonly occurs during 
a genital infection and the ability of C trachomatis to infect amniotic cells has been 
demonstrated in vitro. Most likely, fetal membranes were affected following infection of 
the endometrium. It is possible that the direct damage to the fetal membranes resulting 
from the infection, in combination with endotoxin activity is a significant factor in the 
premature termination of pregnancy. 
 
9.  Maternal IgM at mid-trimester and preterm delivery. Numazaki et al, The Lancet 1999. A 
letter reporting a study with 178 pregnant women of which IgM was detected in ten at 10-
22 weeks of gestation. None of these had any complications during pregnancy or labor. 
Contrarily, they report that the numbers of perinatal complications including preterm 
delivery were significantly higher in IgG and IgA antibody positive pregnant women at 
30 weeks of gestation than in seronegative pregnant women. Insufficient information to 
evaluate the quality of the referred study.   75
 
 
10. Chlamydia trachomatis: impact on human reproduction. Paavonen nad Eggert-
Kruse, Human Reproduction Update 1999. The paper gives thorough theoretical 
background on the issue, with references. Chlamydial PID is the most common 
preventable cause of infertility and adverse pregnancy outcome. Based on the available 
evidence, approximately 20% of women with chlamydial lower genital tract infection 
will develop PID, approximately 4% will develop chronic pelvic pain, 3% infertility and 
2% adverse pregnancy outcome. However, these estimates are based on relatively weak 
evidence. Chlamydial infection fills the general prerequisites for disease prevention by 
screening, i.e. chlamydial infections are highly prevalent, usually asymptomatic, are 
associated with significant morbidity, can be reliably diagnosed, and are treatable. 
Screening programs for C trachomatis will be of paramount importance in the prevention 
of long-term sequelae. The cost of screening is only a fraction of the health care cost 
incurred due to complications resulting from undiagnosed and untreated chlamydial 
infections. Current strategies to control C trachomatis still largely depend on clinic-based 
screening of symptomatic patients, and have not been successful. The development of 
highly sensitive and specific nucleic acid amplification tests for the diagnosis of 
chlamydial infections has been an important advance in the ability to conduct population-
based screening programs to prevent complications. 
The proportion of tubal factor infertility among all infertility ranges from less than 
40% in developed countries to up to 85% in developing countries (WHO 1987). After a 
single episode of PID, the relative risk for tubal factor infertility is approximately 10%, 
and each repeat episode doubles the risk. Studies have demonstrated a strong link 
between serum antibodies to C trachomatis and tubal factor infertility or ectopic 
pregnancy. Ectopic pregnancy is the main cause of maternal mortality in the first 
trimester of pregnancy in developing countries. In addition to infertility and ectopic 
pregnancy, other morbidity is also associated with history of PID, such as chronic pelivc 
pain caused by extraluminal scarring. Chronic pelvic pain following PID occurs in 
between 24% and 75% of women. There is some evidence that C trachomatis may also 
contribute to pregnancy complications other than ectopic pregnancy, including premature 
rupture of membranes, preterm birth, low birth weight and stillbirth. Early pregnancy loss 
ore recurrent pregnancy loss may be induced by asymptomatic C trachomatis infection. 
 
11. The frequency and the role of Chlamydia trachomatis infection in premature labor. 
Kovacs et al, International Journal of Gynecology & Obstetrics 1998. A prospective 
multi center study in Hungary of 6161 pregnant women of whom 362 (5.75%) were C 
trachomatis positive. An association between low birth weight or premature labor and C 
trachomatis, was not found. The perinatal mortality rate was significantly higher in the C 
trachomatis positive patients (3.6 vs. 2.0%). Neonatal morbidity, measured as referrals to 
perinatal intensive care unit was significantly higher among children of C trachomatis 
positive mothers (17.1 vs. 6.3%). In newborns of C trachomatis positive mothers, 
congenital pneumonia developed in 21.8% in the non-treated and only 8.6 in the treated 
group (p<0.001). 
Some of the C trachomatis positive women were treated (“in three of seven 
centers”): it is unclear how many as well as the effect of this treatment. The analysis did 
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Abstracts 
 
1.  Chlamydia trachomatis infection among pregnant women: prevalence and prenatal 
importance. Paul et al, National Medical Journal of India, 1999. This is a small 
epidemiological study of 94 pregnant women between 26 and 30 gestational week and 
172 women presenting in spontaneous labor. There was no association found between 
infection with C trachomatis and low birth weight or prematurity. This study is of 
suboptimal quality. 
 
2.  Chlamydia trachomatis infection in pregnancy: risk factor for an adverse outcome. 
Rastogi et al, British Journal of Biomedical Science 1999. This is a small 
epidemiological study of 122 pregnant women who were tested (culture) for C 
trachomatis, and of whom adverse effects of pregnancy were recorded in 87 of them. 26 
(21%) women were infected with C trachomatis. The authors report an increased risk of 
stillbirth (17 vs. 6%), prematurity (27 vs. 18) and low birth weight (27 vs. 23) in the 
infected women. 
 
3.  Comparison of pregnancy outcome between treated and untreated women with 
chlamydial cervicitis. Rivlin et al, Journal of the Mississippi State Medical Association. 
Of 81 pregnant women with chlamydia, 58 were treated and 23 were not treated. The two 
groups were similar with regards to abortion, preterm rupture of membranes, preterm 
delivery, chorioamnionitis, endometritis, and neonatal and infant complications. The 




Review of C trachomatis-related complications in other literature 
 
Reproductive tract infections: Global impact and priorities for women’s reproductive 
health. Germain et al, Plenum press, New York, 1992. Research on the economic consequences 
of STDs is still very limited. Only one study has attempted to quantify the economic cost of RTIs 
and their complications and sequelae in developing countries: M. Over and P. Piot concluded that 
STDs, excluding HIV infection, account for 5 percent of the total discounted healthy life years 
lost in Sub-Saharan Africa. Few data are available on the complications and sequelae of RTIs 
(adverse outcomes of pregnancy, maternal mortality, cervical cancer, ectopic pregnancy, 
infertility, and chronic pelvic pain).  
Complications and sequelae occur more often in developing countries than in developed 
countries because of cultural barriers to seeking care, restricted access to health care, insufficient 
diagnostic facilities, and antibiotic resistance patterns, among other factors. The cost of treating 
these complications and sequelae are almost certainly much greater than the cost of treating the 
infection itself. While no quantitative data are readily available, hospital admission records from 
gynecology wards suggest that the opportunity costs of these preventable complications are 
substantial. Programs to reduce the incidence of RTIs in the female population and to administer 
early treatment of RTIs will substantially reduce the development of complications and sequelae, 
and have a major impact on the costs of RTIs. 
 
The preterm prediction study: Association of second-trimester genitourinary chlamydia 
infection with subsequent spontaneous preterm birth. Andrews et al, Am J Obst Gyn 2000. 
Although abundant evidence is now available to link certain genital tract infections with 
spontaneous preterm birth, investigations of the association between C trachomatis infection of   77
the female genital tract during pregnancy and subsequent spontaneous preterm birth have 
produced mixed results. Some reports have linked the presence of maternal chlamydia infection 
with low birth weight, premature birth, premature rupture of membranes, and even an increased 
risk of perinatal death (ref). However, such an association with adverse pregnancy outcomes is 
not a universal finding (ref). Most available studies have used insensitive screening tests to 
diagnose C trachomatis infection of the genital tract and also have methodological shortcomings, 
including a limited ability to control for potential confounding variables (ref). The CDC has 
recommended that screening and treatment of genital tract C trachomatis infection be considered 
for pregnant women with certain risk factors to prevent neonatal sequelae resulting from vertical 
transmission of this organism. Because of the conflicting data regarding the association of C 
trachomatis infection with preterm birth and in the absence of data that treatment of this infection 
will prevent preterm birth, however, no recommendations has been made for a screening and 
treatment program expressly to prevent preterm birth. 
 
Disease control priorities in developing countries, chapter 20: HIV infection and sexually 
transmitted diseases. Over and Piot, Oxford Medical Publications, 1992.Two parameters 
important in estimating the burden of STDs are the prevalence of infection and the rate of 
complications and sequelae. The degree of health-seeking behaviour and the quality of health 
services and STD control programs directly control the latter and, by reducing transmission, 
indirectly control the former. The morbidity of STIs occurs mostly between the ages of fifteen 
and forty-five years – not only the sexually most active period in life but also the most 
economically and demographically productive age. 
  Studies in Sweden have shown that 8 to 10 percent of women with gonococcal or 
chlamydial infection develop pelvic inflammatory disease. The annual incidence rate of PID 
among urban women in Sub-Saharan Africa can be estimated at 1 to 3 percent between the ages 
of fifteen and forty-five, with incidence rates of 0.4 to 1.2 percent, and 0.4 to 1.5 percent for 
gonococcal and chlamydial PID, respectively (assuming that 20 to 40 percent of cases of PID are 
du to N gonorrhoeae and 20 to 50 percent to C trachomatis. Half of these cases occur during the 
puerperal period. The annual mortality rate due to PID in this age group could then be 0.1 to 0.5 
per 1000 (assuming 1 percent fatality rate). 
  The annual incidence of bilateral tubal occlusion leading to infertility is estimated at 0.3 
to 1.5 percent in urban women in Sub-Saharan Africa, with gonococci and chlamydia each being 
responsible for 20 to 40 percent of cases (assuming a 15 to 40 percent risk of tubal occlusion after 
one episode of PID). 
  The annual incidence of ectopic pregnancy in urban Africa resulting from PID is 
estimated at 0.01 to 0,04 percent, with an annual mortality rate of 0.001 to 0.005 percent for 
women between 15 and 45.  
  Finally, maternal mortality due to gonococcal and chlamydial infection (post partum 
infectious complications) may be as high as 0,04 to 0.2 percent annually in Sub-Saharan Africa 
(with a maternal mortality rate of 0.5 to 1 percent and a 10 to 20 percent incidence of postpartum 
infections). In general, the overall mortality from STDs is not well defined. It is often a hidden 
mortality and morbidity because of a long latency period between the acute infection and the 
complication or sequelae leading to death.  
  In neonates, conjunctivitis and respiratory disease are the main causes of morbidity due to 
N gonorrhoeae and C trachomatis infection in the mother. The incidence depends on the 
prevalence of these infections in the pregnant women. Disablement from gonococcal neonatal 
infection is due to keratitis and blindness, while, disablement from chlamydial infection results 
mainly from chronic respiratory disease. 
  Per capita annual disease burden of chlamydia in Sub-Saharan Africa 
  Discounted disability-adjusted life-days lost: 8.6 (high prevalence)/0.8 (low prevalence   78
  Discounted productive disability-adjusted life-days lost: 5.8 (high prevalence)/0.5 (low 
prevalence 
  Burden of chlamydia in high-prevalence (incidence 9.5) urban areas 
  Discounted disability-adjusted life-days lost: 4.8 –or saved: 1.3 
  Discounted DALYs saved per case prevented or cured when epidemics independent 
    1. Static benefit 1.05.  
2. Dynamic benefit, core: 43.0, non-core: 4.4  
3. Total benefit core 44.1, non-core 5.5 
Discounted DALYs saved per case prevented or cured when chlamydia increases HIV 
transmission 
  …and so on. 
 
Sexually Transmitted Diseases Treatment Guidelines 2002, CDC: A test for C trachomatis 
should be performed at the first prenatal visit. Women aged <25 years and those at increased risk 
for chlamydia (i.e. new or more than one sex partner) also should be tested during the third 
trimester to prevent maternal postnatal complications and infection in the infant. Screening during 
the first trimester might enable prevention of adverse effects of chlamydia during pregnancy. 
However, evidence for preventing adverse effects during pregnancy is lacking. If screening is 
performed only during first trimester, a longer period exists for acquiring infection before 
delivery. 
 
Chlamydia trachomatis: impact on human reproduction. Paavonen nad Eggert-Kruse, 
Human Reproduction Update 1999. Chlamydial PID is the most common preventable cause of 
infertility and adverse pregnancy outcome. Based on the available evidence, approximately 20% 
of women with chlmayidal lower genital tract infection will develop PID, approximately 4% will 
develop chronic pelvic pain, 3% infertility and 2% adverse pregnancy outcome. Hwoever, these 
estimates are based on relatively weak evidence. Chlamydial infection fills the general 
prerequisites for disease prevention by screening, i.e. chlamydial infections are highly prevalent, 
usually asymptomatic, are associated with significant morbidity, can be reliably diagnosed, and 
are treatable. Screening programmes for C trachomatis will be of paramount importance in the 
prevention of long-term sequelae. The cost of screening is only a fracion of the health care cost 
incurred due to complications resulting from undiagnosed and untreated chlamydial infections. 
Current strategies to control C trachomatis still largely depend on clinic-based screening of 
symptomatic patients, and have not been successful. The development of highly sensitive and 
specific nucleic acid amplification tests for the diagnosis of chlamydial infections has been an 
important advance in the ability to conduct population-based screening programmes to prevent 
complications. 
 
Genital Chlamydial Infections. Peipert, N Engl J Med 2003. C trachomatis is an important 
causal agent in pelvic inflammatory disease, with sequelae including infertility, ectopic 
pregnancy, and chronic pelvic pain (ref.). Up to two thirds of cases of tubal-factor infertility and 
one third of cases of ectopic pregnancy may be attributable to C trachomatis infection (ref). 
Chlamydial infection during pregnancy is associated with a number of adverse outcomes of 
pregnancy including preterm labour, premature rupture of membranes, low birth weight, neonatal 
death, and postpartum endometritis (ref). Chlamydial infection during pregnancy may be 
transmitted to the infant during delivery (ref). An infant born to a mother with active infection has 
a risk of acquiring infection at any anatomical site of 50 to 70 percent. Approximately 30 to 50 
percent of infants born to chlamydia-positive mothers will have conjunctivitis, and at least 50 
percent of infants with chlamydial conjunctivitis will also have nasopharyngeal infection. 
Chlamydial pneumonia develops in about 30 percent of infants with nasopharyngeal infection 
(ref).   79
  There is good evidence that screening women who are at risk for C trachomatis infection 
can prevent reproductive sequelae by reducing the rate of pelvic inflammatory disease (ref). The 
strongest evidence supporting screening in women comes from a large randomized trial of 
screening and treatment at a health maintenance organization in Seattle (ref) among at-risk 
asymptomatic women 18-34 years of age. By the end of the follow-up period, there were 9 
verified cases of PID in the screened group and 33 cases in the usual-care group. Long term 
adverse effects were not addressed. Two ecologic studies in Sweden showed that the rates of both 
ectopic pregnancies and PID were reduced in communities after screening for chlamydial 
infection was adopted (ref). Although data from randomized trials of screening for chlamydial 
infection during pregnancy are lacking, there is some evidence that screening high-risk women 
for C trachomatis during pregnancy can reduce the rate of adverse outcomes of pregnancy. Two 
observational studies showed associations between the treatment of chlamydial infection during 
pregnancy and improved outcomes of pregnancy, including lower rates of premature rupture of 
the membranes, low birth weight, births of infants who were small for their gestational age, and 
neonatal death (ref). 
 
Mass antimicrobial treatment in pregnancy. Temmerman et al, J of Reprod med. Maternal 
genital infection is one of the causes of preterm birth that may be most susceptible to intervention. 
Sexually transmitted diseases, especially syphilis, gonorrhea and chlamydia, are endemic in many 
developing countries and play an important role in perinatal morbidity and mortality (ref STD, 
Holmes et al.). Two case-control studies from Nairobi reported a significant association between 
maternal gonococcal infection and prematurity (ref). In addition, high rates of opthalmia 
neonatorum and postpartum upper genital tract infections were observed; they were significantly 
associated with gonococcal and chlamydial infections (ref). 
 
Chlamydia in Pregnancy: A randomized trial of Azitromycin and erythromycin. Adair et al, 
Obstetrics & Gynecology. Chlamydia infection during pregnancy can cause adverse effects on 
both the gravida and the neonatate, including spontaneous abortion, fetal death, premature rupture 
of membranes, preterm delivery and postpartum endometritis (ref.). Neonatal vertical acquisition 
may result in conjunctivitis and pneumonia. Transmission to the neonatate can occur in more than 
70% of the cases (ref.) 
 
TRIALS 
Improved pregnancy outcome following successful treatment of chlamydial infection. Cohen 
et al. JAMA 1990. Pregnancy outcomes of 224 women successfully treated with erythromycin 
were compared with those of 79 chlamydia-positive women who failed to respond to treatment, 
and 244 chlamydia-free control women. The frequency of premature rupture of membranes, 
premature contractions and small-for-gestational age infants were significantly lower in the 
successfully treated patients when compared with those of the chlamydia positive patients, but not 
significantly different compared to the control patients.  
 
Prematurity and perinatal mortality in pregnancies complicated by maternal chlamydia 
trachomatis infections. Martin et al, JAMA 1982. Prospective study of morbidity associated 
with C trachomatis infection during pregnancy. 18 of 268 women were C trachomatis positive. 
Stillbirth or neonatal death occurred ten times more often among C trachomatis positive women 
than among unifected controls matched for age, marital status, socioeconomic status, and race. 
 
Cervical Chlamydia trachomatis and mycoplasmal infections in preganancy. Epidemiology 
and outcomes. Harrison et al, JAMA 1983. Prospective study of chlamydia and mycoplasma in 
pregnancy. CT in 8%, MH in 23.5%. The cervical infections did not predict low birth weighet, 
abortion, stillbirth, prematurity, or premature rupture of membranes. Only MH predicted   80
endometritis/fever after vaginal delivery (RR 7.3). IgM seropositive CT had more low-birth-
weight infants and more premature rupture of membranes than IgM negative or CT culture 
negative women. Thus, only certain subgroups of infected women may experience adverse 
pregnancy outcomes. 
 
Independent associations of bacterial vaginosis and Chlamydia trachomatis infection with 
adverse pregnancy outcome. Gravett et al, JAMA 1986. Prospective study of pregnancy 
outcome among 534 pregnant women. BV in 19% and CT in 9%. Neonatates born to women with 
BV had lower mean birth weight, and BV was significantly associated with PROM (OR 2), 
preterm labour (OR 2), amniotic fluid infection (OR 2.7), but not with birth weight <2.5 kg. 
Cervical infection with CT was independently associated with preterm premature rupture of the 
membranes, preterm labor and low birth weight (OR 1.5, CI 0.8-2.0). 
 
The preterm prediction study: Association of second-trimester genitourinary chlamydia 
infection with subsequent spontaneous preterm birth. Andrews et al, Am J Obst Gyn 2000. 
This is a retrospective case-control study within The Preterm Prediction Study where 2929 
pregnant women were evaluated longitudinally to determine risk factors for spontaneous preterm 
birth. This study consist of 117 case patients with a spontaneous preterm birth at <37 weeks with 
corresponding matched control subjects.  
After adjustment for risk factors for spontaneous preterm birth, women with C 
trachomatis infection at 24 weeks gestation were 2 times as likely as uninfected women to have a 
spontaneous preterm birth at <37 weeks gestation and 3 times as likely to have a spontaneous 
preterm birth at <35 weeks gestation. Whether universal screening and treatment for C 
trachomatis infection with a sensitive NAAT method for detection would significantly 
reduce spontaneous preterm delivery remains an unanswered question. 
 
A murine model for the study of Chlamydia trachomatis genital infections during 
pregnancy. Pal et al, Infection and immunity, May 1999. Infant mortality in the US has recently 
increased. These high infant mortality rates are mainly due to high rates of premature birth and 
associated low birth weight. Determinants that affect low birth weight include genetic, social, 
environmental and behavioral factors. Infections of the genital tract are considered to account for 
up to 40% of preterm births. Organisms that have been associated with this problem include, 
among others, C trachomatis, N gonorrhoeae, M hominis, Gardnerella vaginalis, Streptococcus 
agalactiae, T vaginalis and U urealyticum. 
  Several studies over the last two decades have attempted to determine the impact that a C 
trachomatis genital infection has on pregnancy outcome. Some of these studies found maternal 
and fetal morbidity and mortality associated with both acute and past chlamydial infections, while 
others did not confirm these data (ref). Most likely, depending on the infecting inoculum, time of 
gestation, and susceptibility of the host, a variety of clinical manifestations ranging from 
asymptomatic infection to termination of pregnancy may occur.  
In our murine model, we have shown that C trachomatis inoculated intravaginally on day 
5 of gestation in mice infects the endometrium and the membranes of the yolk sac, resulting in 
early termination of pregnancy. This is not surprising since chlamydial endometritis commonly 
occurs during a genital infection and the ability of C trachomatis to infect amniotic cells has been 
demonstrated in vitro. Most likely, fetal membranes were affected following infection of the 
endometrium. It is possible that the direct damage to the fetal membranes resulting from the 
infection, in combination with endotoxin activity is a significant factor in the premature 
termination of pregnancy. 
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Conclusion: spontaneous abortion, preterm birth and low birth weight 
 
We have little specific knowledge on what extent infection with C trachomatis has on pregnancy 
outcome, especially in developing countries. This is a very demanding research question, and 
weaknesses in methodology include imperfect sensitivity or specificity of tests and lack of control 
for confounding factors. Differences between studies may be caused by differences in test 
method, focus on acute or chronic infection or gestational time when infection is identified.  
 
Evidence lacking: 
-The prevalence of abortion, preterm birth and low birth weight in the population 
-The extent which C trachomatis infection increases the risk of spontaneous abortion and preterm 
birth, or the proportion of these conditions which are caused by C trachomatis 
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Appendix 6 
PROBABILITY OF CURE WITH DIFFERENT DRUG REGIMENS TO TREAT CHLAMYDIA 
Azitromycin  Erythromycin‡  Doxycycline  Source Patient  group  Correct 
prescription  Compliant  Effectiveness Compliant  Effectiveness Compliant  Effectiveness 














Welte [52] CE-R  Unspecified    100%  95%      80%  95% 
Roberts  [62]  CE-R  Unspecified  100%  100%      75-87%   
Romoren  [32]  OD  Pregnant  women      “low”      
Guaschino [97] R  Unspecified    Effectiveness 95-100% 
Clinical cure rate 89-97% 
Effectiveness 95-100% 
Clinical cure rate 80% 
Effectiveness 88-100% 
Clinical cure rate 94-99% 
Turrentine [103] M  Pregnant women        Clinical cure 95%     
Adimora [45] R 
     
    Thorpe OD 
    Brihmer OD 
    McCormack OD1 
 













Clinical cure rate 80-95% 
NA (100%)    97% 
NA (100%)  100% 
   Effectiveness  99% 
Clinical cure rate  
NA (100%)  99%   
 
NA               97% 
NA               99% 
NA               99%  
Townshend [50] CE  Unspecified  100%  Treatment success rate 90% (80-100%), re-infections included (AB unspecified) 
de Vries [104] CE  Male and female  100%  90%  95%  Based on the same operational research as Postma 
Adair [105] OD  Pregnant women  NA  NA  97.5%  (53.5%)   95.3%     
Rustomjee [72] OD  Female index  NA  100%  100%         
Miller [96] R       99 (93-100)  95 (88-100)  80% (54-89)  86 (72-95)     
Abstracts 
    Silverman OD  
    Bush OD 
    Alger OD 


















Overall cure rate 84.6% 
Overall cure rate 93% 
Overall cure rate 83% 
Overall cure rate 100% 
 
  
CE, Cost-effectiveness study; R, Review; OD, original data; M, meta analysis. †Bacterial cure within 2-4 weeks 
‡ Many studies report side-effects followed by non-compliance to erythromycin. However, the cure-rate is always reported to be higher than the treatment 
failure.   83
A treatment failure may be due to non-compliance, microbiological cure failure or re-infection 
 
Studies, primarily from developing countries, have measured compliance and partner notification in 
randomized, controlled trials [72, 105, 106]. Yet these methods are hampered by methodological 
challenges such as observational bias (patients are likely to perform better in a defined research setting), or 
there may be a self-selection of patients, in that the less conscientious individuals will be lost during the 
follow-up stage. Additionally, most studies have focused on “treatment failures” without being able to tell 
if it is insufficient compliance, incomplete efficacy of the drug or reinfection from an infected partner 
which has caused the failure to obtain cure. 
 
There are few papers published on Medline on patient compliance to STI drugs in developing countries. 
Only clinical cure rates can be measured in the syndromic management of STIs: As it is unknown which 
infection or condition the patient is suffering from, information on drug efficacy or reinfection rates is 
unachievable. Buve et al estimate the proportion of symptomatic patients with a bacterial sexually 
transmitted infection cured by primary health care services in Mwanza, Tanzania. Within this project, 
patients with an STI syndrome assessed at outpatient clinics were requested to report back after 1 week. Of 
the female returners, 69% said they took the full treatment. The authors assume that the selection of dutiful 
patients results in an overestimate of the total compliance rate [79].    84
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